書籍詳細

炎症リウマチ

P.13 掲載の参考文献

• 1) Bywaters EGL: Still's disease in the adult. Ann Rheum Dis 30: 121-133, 1971

• 2) Ohta A, Yamaguchi M, Kaneoka H, et al: Adult Still's disease: review of 228 cases from the literature. J Rheumatol 14: 1139-1146, 1987
  pubmed

• 3) Cabane J, Michon A, Ziza JM, et al: Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years. Ann Rheum Dis 49: 283-285, 1990
  pubmed

• 4) 田中信介, 松本美富士, 大西裕子ら: 全身型発症若年性関節リウマチと成人発症スチル病の臨床的比較検討. リウマチ31: 511-518, 1991

• 5) Uppal SS, Pande IRA, Kumar A, et al: Adult onset Still's disease in northern India: comparison with juvenile onset Still's disease. Br J Rheumatol 34: 429-434, 1995

• 6) Kahn MF: Adult Still's disease. Still many issues unresolved. J Rheumatol 23: 2015-2016, 1996
  pubmed

• 7) Valtonen JM, Kousunen TU, Karjalainen J, et al: Serological findings in patients with acute syndromes fulfilling the proposed criteria of adult onset Still's disease. Scand J Rheumatol 26: 342-345, 1997

• 8) Pouchot J, Ouakil H, Debin ML, et al: Adult Still's disease associated with acute human parvovirus B19 infection, Lancet 341: 1280-1281, 1993
  pubmed

• 9) Godeau B, Palazzo E, Morinet F, et al: Is Still's disease associated with parvovirus B19 infection? Lancet 345: 59, 1994

• 10) Hoshino T, Ohta A, Nakao M, et al: TCR γδ+T cells in peripheral blood of patients with adult Still's disease. J Rheumatol 23: 124-129, 1996

• 11) Wouters JMGW, Reekers P, van de Putte LBA: Adult onset Still's disease. Disease course and HLA associations. Arthritis Rheum 29: 415-418, 1986

• 12) de Benedetti F, Massa M, Robbioni P, et al: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34: 1158-1163, 1991
  pubmed

• 13) Mangge H, Kenzian H, Gallistl S, et al: Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 38: 211-220, 1995
  pubmed

• 14) Rooney M, David J, Symons J, et al: Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 34: 454-460, 1995

• 15) Hoshino T, Ohta A, Yang D, et al: Elevated serum IL-6, IFN-γ and TNF-α levels in patients with adult Still's disease. J Rheumatol 25: 396-398, 1998

• 16) Stephan JL, Zeller J, Hubert PH, et al: Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 11: 451-456, 1993

• 17) 野村昌作, 福原資郎: Hemophagocytic syndrome. リウマチ病セミナーVIII (七川歡次監修), pp164-168, 大阪, 永井書店, 1997

• 18) 久野千津子, 中村稔, 真弓武仁ら; 成人スチル病として経過観察中に, 急性肝炎を発症したhemophagocytic syndromeの1例. 日臨免疫会誌 18: 256-264, 1995

• 19) Wakai K, Ohta A, Tamakoshi A, et al: Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7: 221-225, 1997
  pubmed

• 20) Magadur-Joly G, Billaud E, Barrier JH, et al: Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54: 587-590, 1995
  pubmed

• 21) Tamura K, Kubota K, Kurabayashi H, et al: Elderly onset of adult Still's disease: report of a case. Clin Rheumatol 13: 117-118, 1994
  pubmed

• 22) 大田明英, 牛山理, 鈴木憲明ら: 成人Still病の治療と経過-全国調査集計より-. 厚生省特定疾患自己免疫疾患調査研究班平成7年度研究報告書, pp163-165, 1996

• 23) Ohta A, Yamaguchi M, Tsunematsu T, et al: Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol 17: 1058-1063, 1990

• 24) Pouchot J, Sampalis JS, Beaudet F, et al: Adult Still's disease: manifestations, disease course and outcome in 62 patients. Medicine (Baltimore) 70: 118-136, 1991
  pubmed

• 25) 大田明英, 山口雅也: 成人Still病の関節症状. 内科 71: 451-454, 1993

• 26) 山口雅也, 大田明英: 成人Still病にみられる皮疹.日医新報 3469: 37-40, 1990

• 27) Torinuki W, Funyu T: Adult Still's disease manifesting as erythema nodosum. J Dermatol 23: 216-217, 1996

• 28) 斎藤文子, 佐藤由紀夫, 宮田昌之ら: 非定型的な皮疹を呈した成人Still病の2例. リウマチ38: 516-522, 1998.

• 29) Nguyen KHY, Weisman MH: Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature. J Rheumatol 24: 592-597, 1997

• 30) 塩沢俊一: リウマチ病とフェリチン. リウマチ病セミナーVIII (七川歡次監修), pp181-190, 大阪, 永井書店, 1997

• 31) 大田明英, 牛山理, 鈴木憲明ら: 成人Still病分類基準の見直しについて. 厚生省特定疾患自己免疫疾患調査研究班平成7年度研究報告書, pp160-162, 1996

• 32) Schwarz-Eywill M, Heilig B, Bauer H, et al: Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 51: 683-685, 1992
  pubmed

• 33) van Reeth C, le Moel G, Lasne Y, et al: Serum ferritin and isoferritins are tools for diagnosis of active adult Still's diagnosis. J Rheumatol 21: 890-895, 1994

• 34) Motoo Y, Ohta H, Okai T, et al: Adult onset Still's disease: hepatic involvement and various serum markers relating to the disease activity. Jpn J Med 30: 247-250, 1991

• 35) Coffernils M, Soupart A, Pradier O, et al: Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 19: 1425-1427, 1992

• 36) Rogers JT, Bridges KR, Durmowicz GP, et al: Translational control during the acute phase response ferritin synthesis in response to interleukin-1. J Biol Chem 265: 14572-14578, 1990
  pubmed

• 37) Adams PC, Powell LW, Halliday JW: Isolation of a human hepatic ferritin receptor. Hepatology 8: 719-721, 1988
  pubmed

• 38) Yamaguchi M, Ohta A, Tsunematsu T, et al: Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992

• 39) Masson C, le Loet X, Liote F, et al: Comparative study of 6 types of criteria in adult Still's disease, J Rheumatol 23: 495-497, 1996
  pubmed

• 40) 柏木平八郎: 内科診療の進歩 不明熱の臨床. 日内会誌 75: 1214-1218, 1986

• 41) Shoji S, Imamura A, Imai Y, et al: Fever of unknown origin: a review of 80 patients from the Shin' etsu area of Japan from 1986-1992. Internal Medicine 33: 74-76, 1994

• 42) 大田明英, 山口雅也: リウマチ性疾患におけるスチル病の位置づけ. リウマチ 33: 410-415, 1993

• 43) Meyerhoff J: Familial mediterranean fever: Report of a large family, review of the literature, and discussion of the frequency of amyloidosis. Medicine (Baltimore) 59: 66-77, 1980
  pubmed

• 44) Drenth JPH, Haagsma CJ, van der Meer JWM, and the international hyper-IgD study group: Hyperimmunoglobulinemia D and periodic fever syndrome. Medicine 73: 133-144, 1994

• 45) 長澤浩平: 成人スチル病の病態と治療. 日内会誌 87: 417-421, 1998

• 46) Akritidis N, Giannakakis I, Giouglis T: Ferritin levels and response to treatment in patients with adult Still's disease. J Rheumatol 23: 201-202, 1996

• 47) Aydintug AO, d'Cruz D, Cervera R, et al: Low dose methotrexate treatment in adult Still's disease. J Rheumatol 19: 431-435, 1992.

• 48) Fujii T, Akizuki M, Kameda H, et al: Methotrexate treatment in patients with adult onset Still's disease-retrospective study of 13 Japanese cases. Ann Rheum Dis 56: 144-148, 1997
  pubmed

• 49) Shojania K, Chalmers A, Rangno K: Cyclosporin A in the treatment of adult Still's disease. J Rheumatol 22: 1391-1392, 1995
  pubmed

• 50) Kulke R, Koeppel M, Hey D: Treatment of adult Still's disease with intravenous immunoglobulin. Lancet 347: 337, 1996

• 51) 戸谷義幸, 高木信嘉, 平和伸仁ら: 二重濾過血漿交換療法が著効した成人発症Still病の3例. 日内会誌 82: 1713-1714, 1993

• 52) de Vita S, Ferraccioli GF, Si Poi E, et al: High dose intravenous immunoglobulin therapy for rheumatic disease: Clinical relevance and personal experience. Clin Exp Rheumatol 14 (Suppl 15): S85-S92, 1996

• 53) Prieur AM: Intravenous immunoglobulins in Still's disease: still controversial, still unproven. J Rheumatol 23: 797-800, 1996
  pubmed

• 54) Wouters JMGW, van de Putte LBA: Adult-onset Still's disease-clinical and laboratory features, treatment and progress of 45 cases. Q J Med 61: 1055-1065, 1986

• 55) Bjorkengren AG, Pathria MN, Sartoris DJ, et al: Carpal alterations in adult onset Still disease, juvenile chronic arthritis, and adult onset rheumatoid arthritis: comparative study. Radiology 165: 545-548, 1987
  pubmed

• 56) Sampalis JS, Esdaile JM , Medsger TA, et al: A controlled study of the long-term prognosis of adult Still's disease. Am J Med 98: 384-388, 1995

• 57) 中野恭幸, 八木田正人, 新木英薫ら: 細菌性髄膜炎との鑑別が困難であった成人発症Still病の1例. 日内会誌 84: 287-289, 1995

• 58) Garrote FJ, Marco J, Obeso G, et al: Aseptic meningitis and focal central nervous system involvement in a case of adult onset Still's disease. J Rheumatol 20: 765-767, 1993

• 59) 横山雅子, 諏訪昭, 篠沢妙子ら: 成人呼吸促迫症候群および播種性血管内凝固症候群を合併した成人発症スチル病の1例. 日臨免疫会誌 18: 207-214, 1995.

• 60) Boki KA, Tsirantonaki MJ, Markakis K, et al: Thrombotic thrombocytopenic purpura in adult Still's disease. J Rheumatol 23: 385-387, 1996
  pubmed

• 61) Moder KG, Miller TD, Allen GL: Cardiac tamponade: an unusual feature of adult onset Still's disease. J Rheumatol 22: 180-182, 1995
  pubmed

• 62) Ueda T, Mizushige K, Sakamoto S, et al: Adult Still's disease with myocardial dysfunction induced by microangiopathy. Jpn Circ J 61: 74-77, 1997
  pubmed

• 63) van Hoeyweghen RJ, De Clerck LS, Van Offel JF, et al: Interstitial lung disease and adult-onset Still's disease. Clin Rheumatol 12: 418-421, 1993
  pubmed

• 64) Dino O, Provenzano G, Giannuoli G, et al: Fulminant hepatic failure in adult onset Still's disease. J Rheumatol 23: 784-785, 1996
  pubmed

• 65) Sanchez Loria DM, Moreno Alvarez MJ, Barcelo HA, et al: Sjogren's in adult Still's disease? Clin Rheumatol 15: 133-136, 1996

• 66) Ishii T, Sasaki T, Muryoi T, et al: Systemic amyloidosis in a patient with adult onset Still's disease. Internal Medicine 32: 50-52, 1993

P.23 掲載の参考文献

• 1) Jaksch-Wartenhorst R: Polychondropathia. Wien Arch Inn Med 6: 93-100, 1923

• 2) Pearson CM, Kline HM, Newcomer VD: Relapsing polychondritis. N Eng J Med 263: 51-58, 1960

• 3) Eng J, Sabanathan S: Airway complications of relapsing polychondritis. Ann Thorac Surg 51: 686-692, 1991

• 4) 畑中英一: Relapsing polychondritis, リウマチ病IV (七川歡次編), pp26-35, 大阪, 永井書店, 1977

• 5) 鈴木光子, 内田和仁, 長野正裕ら: 頑固な肋軟骨部痛で発症し高度気管狭窄症状を示した反復性多発軟骨炎の1例. 本邦53症例の文献的考察. 日胸疾会誌21: 665-671, 1983

• 6) 島田朗, 菊池正夫, 石田明ら: 抗type II collagen抗体を検出した再発性多発性軟骨炎の1例. 内科71: 590-592, 1993

• 7) 井上康二, 七川歡次, 西岡淳一: Relapsing polychondritis. リウマチ病VIII (七川歡次編), pp 22-38, 大阪, 永井書店, 1986

• 8) McAdam LP, O'Hanlon MA, Bluestone R, et al: Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine 55: 193-215, 1976

• 9) Isaak BL, Liesegang TJ, Michet CJ Jr: Ocular and systemic findings in relapsing polychondritis. Ophthalmology 93: 681-689, 1986
  pubmed

• 10) Yamazaki N, Yamata K, Hannya H, et al: A case of relapsing polychondritis associated with aortic insufficiency. Jpn Heart J 7: 188-195, 1966

• 11) Rosso AD, Petix NR, Pratesi M, et al: Cardiovascular involvement in relapsing polychondritis. Semin Arthritis Rheum 26: 840-844, 1997

• 12) Weinberger A, Myers AR: Relapsing polychondritis associated with cutaneous vasculitis. Arch Dermatol 115: 980-981, 1979
  pubmed

• 13) Firestein GS, Gruber HE, Weisman MH, et al: Mouth and genital ulcers with inflamed cartilage-MAGIC syndrome. Am J Med 79: 65-72, 1985
  pubmed

• 14) Chang-Miller A, Okamura M, Torres VE, et al: Renal involvement in relapsing polychondritis. Medicine 66: 202-217, 1987
  pubmed

• 15) Hansilk T, Wechsler B, Piette JC, et al: Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 12: 539-541, 1994

• 16) Arkin CR, Masi AT: Relapsing polychondritis. Semin Arthritis Rheum 5: 41-62, 1975
  pubmed

• 17) Papo T, Piette JC, Le TH, et al: Antineutrophil cytoplasmic antibodies in polychondritis. Ann Rheum Dis 52: 384-385, 1993

• 18) Damiani JM, Levine HL: Relapsing polychondritis: report og ten cases. Laryngoscope 89: 929-944, 1979

• 19) Foidart JM, Abe S, Martin GR, et al: Antibodies to type 11 collagen in relapsing polychondritis. N Eng J Med 299: 1203-1207, 1978

• 20) Alsalameh S, Mollenhauer J, Scheuplein F, et al: Perferential cellular and humoral immune reactivites to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol 20: 1419-1424, 1993

• 21) Lang B, Rothenfusser A, Lanchbury JS, et al: Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 36: 660-664, 1993
  pubmed

• 22) Barranco VP: Treatment of relapsing polychondritis with dapsone. Arch Dermatol 112: 1286-1288, 1976
  pubmed

• 23) Askali AD: Colchicine for treatment of relapsing polychondritis. J Am Acad Dermatol 10: 507-510, 1984

• 24) Svenson KLG, Holmdahl R, Klareskog L, et al: Cyclosporine A treatment in a case of relapsing polychondritis. Scand j Reumatol 13: 329-333, 1984

• 25) Michet CJ, McKenna CH, Luthra HS, et al: Relapsing polychondritis: survival and predicive role of eraly disease manifestations. Ann Int Med 104: 74-78, 1986

P.29 掲載の参考文献

• 1) LS: Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol 3: 241-245, 1975

• 2) Pearson CM: Polimyositis/Dermatomyositis. In: Arthritis and Allied Conditions g th ed (Ed, McCarty DJ), p742, Philadelphia, Lea and Febiger, 1979

• 3) Bohan A, Peter JB: Polymyositis and dermatomyositis (First of two parts) . N Engl J Med 292: 344-347, 1975
  pubmed

• 4) Rockerbie NR, Woo TY, Callen JP, et al: Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20: 629-632, 1989
  pubmed

• 5) Euwer RL, Sontheimer RD: Amyopathic dermatomyositis (dermatomyositis sine myositis) . J Am Acad Dermatol 24: 959-966, 1991
  pubmed

• 6) Euwer RL, Sontheimer RD: Amyopathic dermatomyositis: a review. J Invest Dermatol 100: 124 S-127S, 1993

• 7) Fudman EJ, Schnitzer TJ: Dermatomyositis without creatine kinase elevation. a poor prognostic sign. Am J Med 80: 329-332, 1986
  pubmed

• 8) Takizawa H, Shiga J, Moroi Y, et al: Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 14: 102-107, 1987
  pubmed

• 9) 五十嵐敢, 前田恵治, 渋谷知加子ら: 皮膚筋炎における急速進行性線維化性肺胞炎の検討. 第29回日本胸部疾患学会総会抄録集, p337, 1989

• 10) Fernandes L, Goodwill CJ: Dermatomyositis without apparent myositis, complicated by fibrosing alveolitis. J R Soc Med 72: 777-779, 1979
  pubmed

• 11) Fergusson RJ, Davidson NM, Nuki G, et al: Dermatomyositis and rapidly progressive fibrosing alveolitis. Thorax 38: 71-72, 1983
  pubmed

• 12) 滝沢始, 日高紀子, 秋山一男ら: 多発性筋炎, 皮膚筋炎に伴う間質性肺炎.肺線維症に関する臨床, 病理学的検討. 日胸疾会誌 23: 528-536, 1985

• 13) 高林克日己, 倉沢和宏, 杉山隆夫ら: 皮膚筋炎・多発性筋炎にみられる急性びまん性肺疾患の臨床像と予後. 日本臨床免疫学会会誌 14: 122-130, 1991

• 14) 滝沢始, 鈴木直仁, 柳川崇ら: 多発性筋炎, 皮膚筋炎に伴う間質性肺炎の予後に関する検討-とくに予後不良群について-. 日胸疾会誌 34: 1093-1097, 1996

• 15) Maeda K, Kimura R, Komuta K, et al: Cyclosporine treatment for polymysitis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 26: 24-29, 1997
  pubmed

• 16) 前田恵治, 小牟田清, 北田清吾ら: 皮膚筋炎に伴う急速進行性間質性肺炎の治療: 3症例の検討. 第42回日本リウマチ学会総会抄録集, p411, 1998

• 17) 縄田泰史: 膠原病の心・肺病変とその対応. 皮膚筋炎と間質性肺炎. 日内会誌85: 1850-1854, 1996

• 18) 田原潔, 西谷皓次, 久川奈緒子ら: 間質性肺炎を合併したAmyopathic dermatomyositisの1例. リウマチ 37: 714-718, 1997

• 19) 時山国大, 田川博章, 横田英介ら: 急速に進行した間質性肺炎により死亡した Amyopathic Dermatomyositisの2例. リウマチ 30: 204-211, 1990

• 20) 後藤佳子, 伊崎誠一, 北村啓次郎: Amyopathic Dermatomyositisの1例. 皮膚臨床34: 1083-1086, 1992

• 21) 外山晃, 片岡裕一, 堀池重治ら: 呼吸不全を主徴としたamyopathic dermatomyositisの1例. 日救急医会関東誌14: 620-621, 1993

• 22) 藤田弘, 黒川滋子, 今泉俊資ら: 致命的な間質性肺炎を合併したAmyopathic Dermatomyositisの1例. 皮膚臨床37: 463-466, 1995

• 23) 二宮淳也, 中林淳浩, 中村哲雄ら: 間質性肺炎を合併し死亡したAmyopathic Dermatomyositisの1例. 皮膚37: 573-576, 1995

• 24) 豊嶋幹生, 佐藤篤彦, 千田金吾ら: Amyopathic dermatomyositisに伴う間質性肺炎の臨床病理学的検討. 日胸疾会誌35: 281-287, 1997

• 25) 長谷川嘉哉, 加藤孝宣, 上村晶代ら: 高度な肺合併症を伴ったいわゆるAmyopathic Dermatomyositisと考えられる一例. 中部リウマチ23: 168-169, 1992

• 26) Cosnes A, Amaudric F, Gherardi R, et al: Dermatomyositis without muscle weakness. Arch Dermatol 131: 1381-1385, 1995
  pubmed

P.37 掲載の参考文献

• 1) Bruce H, Jerry GP: Stress and rheumatoid arthritis: an integrative review. Arthritis care and research 11: 135-145, 1998

• 2) Laurence AB: Psychosocial factors and arthritis. Primer on rheumatic diseases 10: 569-573, 1996

• 3) Silman AJ, Macgregor AJ, Thompson W, et al: Twin concordnce rates for rheumatoid arthritis: results from a nation wide study. Br J Rheum 32: 903-907, 1993

• 4) Holmes TH, Rahe RH: The social readjustment rating scale. J Psychosom Res 11: 213-218, 1937

• 5) 橋本明: 慢性関節リウマチ. 保険同人社: 161, 1997

• 6) 片渕俊彦: ストレスと免疫系. 感染炎症免疫28: 106-115, 1988

• 7) Pincus T, Leigh FC: Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chron Dis 38: 973-984, 1985

• 8) Weinblatt ME, Maier AL, Emery P: Substantial placebo response in active rheumatoid arthritis (RA) . Arthritis Rheum 33: 152, 1990

• 9) Silman AJ, Hochberg MC: Epidemiology of the rheumatic diseases. Oxford, Oxford University Press, 1993

• 10) 西風脩: 内分泌学の新展開: Dehydroepiandrosterome 17-KS-Sulfates (17-KS-S) とは. 臨床病理46: 520-528, 1998

P.44 掲載の参考文献

• 1) Granadino B, Beltran-Valero de Bernabe D, Fernadez-Canon JM, et al: The human homogentisate 1, 2-dioxygenase (HGO) gene. Genomics 43: 115-122, 1997

• 2) Van Offel JF, De Clerk LS, Francex LM, et al: The clinical manifestations of ochronosis: A review. Acta Clinica Belgica 50: 358-362, 1995

• 3) Cortina R, Astudillo A, Gosalbez F, et al: Familial ochronosis. Europ Heart J 16: 285-286, 1995

• 4) Ishikawa H, Hirohata K: An electron microscopic observation of the synovial membrane and articular cartilage in a patient with ochronosis. Rhumachi 22: 321-328, 1982

• 5) Levine HD, Parisi AF, Holdsworht DE, et al: Aortic valve replacement for ochronosis of the aortic valve. Chest 74: 466-467, 1978

• 6) 今中徹, 武仲美孝, 吉川満喜男ら: オクロノーシスに伴う付着部病変. 第19回日本リウマチ・関節外科学会抄録集, p138, 10月18, 19日, 1991

• 7) 山本基, 織田弘美, 久我芳昭ら: オクロノーシスにおけるenthesisの変化. 臨床リウマチ 8:180-189, 1996

• 8) Kontinen YT, Hoikka V, Landtman M, et al: Ochronosis: areport of a case and a review of literature. Clin Exp Rheumatol 7: 435-444, 1989

• 9) Corra T, Zaccala M, Galante M: Ochronotic arthropathy: rapid destructive hip osteoarthritis associated with metabolic disease. Clin Rheumtol 14: 474-477, 1995

• 10) Dom K, Pittevils T: Ochronotic arthropathy: The black hip case report and review of the lirerature. Acta Orthop Belgica 63: 122 125, 1997

• 11) Van Offel JF, De Clerck LS, Francx LM, et al: Apatient with ochronotic arthropathy and spondylopathy: a difficult differential diagnosis with spondylitis ankylosans. Clin Exp Rheumatol 13: 259-261, 1995

• 12) 島本敬三, 村田紀和: THRを施行したオクロノーシスの一例. 臨床リウマチ 7: 171-177, 1995

P.54 掲載の参考文献

• 1) 大田寛, 七川歡次, 前田晃ら: 慢性関節リウマチの死因調査 (384例) . 平成8年度特定疾患調査研究報告書 (大阪骨・関節難病研究会), 骨 25-48頁, 大阪府衛生部, 大阪府特定疾患研究会, 1997

• 2) 鈴木厚, 小井戸則彦, 大曽根康夫ら: 慢性関節リウマチ140例の死因に関する検討. リウマチ34: 601-607, 1994

• 3) 吉沢久嘉, 工藤洋, 岩野邦男ら: 慢性関節リウマチの死因に関する研究-117RA死亡例の解析-. リウマチ30: 255-263, 1990

• 4) Jurik KG, Graudal H: Pleurisy in rheumatoid arthritis, Scand J Rheumatol 12: 75-80, 1983
  pubmed

• 5) Jurik AG, Davidsen D, grandal H: Prevalance ofpulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol 11: 217-224, 1982

• 6) Perez T, Dansin E, Wallaert B, et al: Manifestations pleuro-pulmonaires de la polyarthrite rheumatoide. Rev Mal Resp 8: 169-189, 1991

• 7) Faurschou HE, Francis D, Faarup P: Thoracoscopic, histological, and clinical findings in nine cases of rheumatoid pleural effusion. Thorax 40: 371-375, 1985

• 8) 奥田恭章, 高杉潔, 今井淳子ら: 高分解能CTによる慢性関節リウマチにおける間質性肺炎/肺線維症の検討-その臨床像について-.リウマチ33: 12-19, 1993

• 9) Frank ST, Weg JG, Harklerord LE, et al: Pulmonary dysfunction in rheumatoid disease. Chest 63: 27-34, 1973

• 10) Linstow M, Ulrik CS, Kriegbaum NJ, et al: An 8-year follow-up of pulmonary function in patients with rheumatoid arthritis. Rheumatol Int 14: 115-118, 1994
  pubmed

• 11) 奥田恭章, 高杉潔, 倉田典之ら: 慢性関節リウマチにおける肺病変-気管支洗浄液を中心として-. リウマチ33: 302-309, 1993

• 12) Garcia JGN, Parhemi N, Killam D, et al: Bronchioalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Dis 133: 450-454, 1986

• 13) Weinberger SE, Kelman JA, Elson NA, et al: Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med 89: 459-466, 1978
  pubmed

• 14) 境田博之: 慢性関節リウマチの肺病変におけるIgGリウマトイド因子の検討. リウマチ35: 671-677, 1995

• 15) Alegre J, Teran J, Alvarez B, et al: Successful use of ciclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis. Arthritis Rheum 33: 1594-1596, 1990

• 16) 鈴木厚, 増田隆夫, 小井戸則彦ら: 膠原病に合併した間質性肺炎・肺線維症における各種血清マーカーの検討-CYFRA21-1の臨床的意義-. リウマチ36: 837-843, 1996

• 17) Kakala M, Ruuska P, Hameenkoppi R, et al: Diffuse interstitial lung disease in rheumatoid arthritis: views on immunological and HLA finding. Scand J Rheumatolol 15: 368-376, 1986

• 18) Geddes DM, Webley M, Brewerton DA: α1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet 19: 1049-1050, 1977

• 19) Martel W, Abell MR, Mikkelsen WM, et al: Pulmonary and pleural lesions in rheumatoid disease. Radiology 90: 941-953, 1968

• 20) Remy-Jardin M, Remy J, Cortet B, et al: Lung changes in rheumatoid arthritis: CT findings. Radiology 193: 375-382, 1994
  pubmed

• 21) Helmer R, Galvin J, Hunninghake: pulmonary manifestations associated with rheumatoid arthritis. Chest 100: 235-238, 1991

• 22) Jolles H, Moseley PL, Peterson MW: Nodular pulmonary opacities in patients with rheumatoid arthritis: a diagnostic dilemma. Chest 96: 1022-1025, 1989
  pubmed

• 23) Koeger AC, Lang T, Alcaix D, et al: Silica associated connective tissue disease, Medicine 74: 221-237, 1995
  pubmed

• 24) Cooney TP: Interrelationship of chronic eosinophilic pneumonia, bronchiolitis obliterans, and rheumatoid disease: a hypothesis. J CIin Pathol 34: 129-137, 1981

• 25) Turton CW, Williams G, Green M: Cryptogenic obliterative bronchiolitis in adults. Thorax 36: 805-810, 1981
  pubmed

• 26) Hakala M, Paakko P, Huhti E, et al: Open lung biopsy of patients with rheumatoid arthritis. Clin Rheumatol 9: 452-460, 1990
  pubmed

• 27) Ippolito JA, Palmer L, Spector S, et al: Bronchitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 23: 70-78, 1993
  pubmed

• 28) Hassan WU, Keaney NP, Holland CD, et al: High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 54: 308-310, 1995
  pubmed

• 29) McDonagh J, Greaves M, Wright AR, et al: High resolution computed tomography of the lung in patients with rheumatoid arthritis and interstitial lung disease. Brit J Rheumatol 33: 118-122, 1994

• 30) McMahon MJ, Swinson DR, Shettar S, et al: Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis 52: 776-779, 1993
  pubmed

• 31) Shadick NA, Fanta CH, Weinblatt ME, et al: Bronchietasis. A late feature of severe rheumatoid arthritis. Medicine 73: 161-170, 1994

• 32) Schnabel A, Gross W: Low dose methotrexate in rheumatoid disease. Efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 23: 310-327, 1994
  pubmed

• 33) 奥和美: 慢性関節リウマチにおける薬剤性肺罹患. リウマチ病セミナーIII (七川歡次編), pp207-217, 大阪, 永井書店, 1992

• 34) 大曽根康夫, 岡野裕, 亀田秀人ら: 慢性関節リウマチにおけるメトトレキセート療法の副作用-とくに汎血球減少症と間質性肺炎の背景因子に関する検討, リウマチ37: 16-23, 1997

• 35) 古谷武文, 都外川新, 中島亜矢子ら: 慢性関節リウマチにおける低用量メトトレキセート療法の有害事象-自験276例での検討-.リウマチ36:746-752, 1996

• 36) Alarcon GS, Kremmer JM, Macaluso M, et al: Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. Ann Intern Med 127: 356-364, 1997

• 37) Cottin V, Tebib J, Massonnet B, et al: Pulmonary function in patients receiving long-term lowdose methotrexate. Chest 109: 933-938, 1996
  pubmed

• 38) Begin R, Radom V, Lantin A, et al: Stiffness of the rib cage in a subset of rheumatoid patients. Lung 166: 141-148, 1988

• 39) Gorini M, Ginanni R, Spinelli A, et al: Inspiratory muscle strength and respiratory drive in patients with rheumatoid arthritis. Am Rev Resp Dis 142: 289-294, 1990
  pubmed

P.66 掲載の参考文献

• 1) Koopman WJ (ed): Arthritis and allied conditions. 13 ed, Baltimore, Williams and Wilkins, 1997

• 2) Klippel JH: Dieppe PA (ed): Rheumatology. led, St. Louis, Mosby, 1994

• 3) Ibid. 2ed, 1998

• 4) 田中清介, 福田寛二: 変形性関節症, 東京, メジカルビュー社, 1997

• 5) Levine JD, Goetzl EJ, Basbaum AI: Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides. Rheumatic Dis Clin North Am 13: 369-383, 1987

• 6) 仙波恵美子: 痛みとproto-oncogeneの発現. リウマチ病セミナーV (七川歡次編), pp212-223, 大阪, 永井書店, 1994

• 7) Julkunen H, Rasanen JA, Kataja J: Severe trauma as an etiologic factor in rheumatoid arthritis. Scand J Rheumatol 3: 97-102, 1974
  pubmed

• 8) Wallace DJ: The role of stress and trauma in rheumatoid arthritis and systemic lupus erythematosus. Semin Arthritis Rheum 16: 153-157, 1987
  pubmed

• 9) 坂田師通: 非麻痺側に慢性関節リウマチを発症した片麻痺患者の一例. リウマチ科18: 490-492, 1997

• 10) 大口義人, 庄司功, 内田均ら: 神経麻痺がリウマチ性疾患に及ぼす保護作用の機序に関する検討-自験例を中心として-. リウマチ科19: 319-324, 1998

• 11) Olivieri I, Gemignani G, Christou C, et al: Trauma and seronegative spondyloarthropathy: report of two more cases of peripheral arthritis precipitated by physical injury. Ann Rhem Dis 48: 520-521, 1989

• 12) 福田眞輔: Reflex sympathetic dystrophy-最近の知見-. リウマチ病セミナーIII (七川歡次編), pp147-152, 大阪, 永井書店, 1992

• 13) 大田寛, 小瀬弘一: 脊椎のalgodystrophy. リウマチ病セミナーIV (七川歡次編), pp59-66, 大阪, 永井書店, 1993

• 14) Rush PJ: The rheumatic manifestations of traumatic spinal cord injury. Semin Arthritis Rheum 19: 77-89, 1989

• 15) 七川歡次, 辻本正記, 小瀬弘一ら: 付着部炎について. リウマチ病V (七川歡次編), pp39-70, 大阪, 永井書店, 1979

• 16) Magnusson T: Extracervical symptoms after whiplash trauma. Cephalalgia 14: 223-227, 1994

• 17) Bulskila D, Neumann L, Vaisberg G, et al: Increased rates of fibrornyalgia following cervical spine injury. Arthritis Rheum 40: 446-452, 1997

• 18) 本郷一郎: 結合組織炎症候群. リウマチ病セミナーI (七川歡次編), pp95-111, 大阪, 永井書店, 1990

• 19) 西岡淳一: Fibromyalgiaのレゾンデートル, リウマチ病セミナーV (七川歡次編), pp69-77, 大阪, 永井書店, 1994

• 20) 西林保朗: 職業とリウマチ病, リウマチ病セミナーVII (七川歡次編), pp112-128, 大阪, 永井書店, 1996

• 21) Aaron LA, Bradley LA, Alarcon GA, et al: Perceived physical and emotional trauma as precipitating events in fibromyalgia. Arthritis Rheum 40: 453-460, 1997

• 22) 久米田靖郎, 行岡正雄, 七川歡次ら: 右示指切断後Fibromyalgia Syndromeを呈した99mTcで胸骨部にup-takeを認める1例. 第12回日本臨床リウマチ学会 (抄録), 1997

• 23) Seligman DA, Pullinger AG: A multiple stepwise logistic regression analysis of trauma history and 16 other history and dental cofactors in females with temporomandibular disorders. J Orofacial Pain 10: 351-360, 1996
  pubmed

• 24) Higgs PE, Young VL: Cumulative trauma disorders. Clin Plastic Surg 23: 421-433, 1996
  pubmed

• 25) 吉野良平: 音楽家とリウマチの訴え. リウマチ病セミナーII (七川歡次監修), pp146-154, 大阪, 永井書店, 1991

• 26) Takenaka Y, Kahan A, Amor B: Experimental autoimmune spondylodiscitis in rats. J Rheumatol 13: 397-400, 1986
  pubmed

• 27) 塩沢俊一, 川崎博樹, 林幸子ら: RAの関節破壊と発症機構の研究. 関節の外科25: 75-84, 1998

P.75 掲載の参考文献

• 1) 植木宏明: 膠原病とその類症. 皮膚科専門医テキスト (朝田康夫ら編), P371, 東京, 南江堂, 1992

• 2) 森俊二: 強皮症診断の手引き. 難病研究医学財団編, 1990

• 3) LeRoy EC: Increased collagen synthesis by scleroderma skin fibroblasts in vitro. A possible defect in the regulation or activation of the sclerodermma fibroblasts. J Clin Invest 54: 880-889, 1974
  pubmed

• 4) 新海宏, 黒田啓: 強皮症皮膚線維芽細胞における細胞外マトリックス関連遺伝子発現について. 厚生省特定疾患強皮症調査研究班平成7年度報告書, pp53-58, 1994

• 5) 新海宏, 岡本修:強皮症皮膚における45KD蛋白質の発現. 厚生省特定疾患強皮症調査研究班平成4年度報告書, pp29-35, 1992

• 6) 新海宏, 岡本修:細胞外マトリックス45KD蛋白質および関連物質. 厚生省特定疾患強皮症調査研究班平成5年度報告書, pp15-18, 1993

• 7) Hermann K, Boehme HJ: Effect of cytokines and growth factors on fibroblast activity. In: Connective Tissue Diseases of the Skin (Eds, Lapiere C, Krieg T), pp157-176, New York, Mercel Dekker Inc, 1993

• 8) Kulozik M, Hogg A Lankat-Buttgereit B, Krieg T: Co-locarization of transforming growth factor beta 2 with alpha I (I) procollagen mRNA in tissue section of patients with systemic sclerosis. J Clin invest 86: 917-922, 1990
  pubmed

• 9) Isaka Y, Brees DK, Ikegaya K, et al: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Medicine 2: 418-423, 1996
  pubmed

• 10) 斎藤一郎, 宮坂信之, 片山一朗ら: 強皮症皮膚病変局所におけるサイトカインならびに細胞接着分子の発現. 強皮症調査研究班平成4年度研究報告書, pp60-65, 1993

• 11) 西山茂夫, 衛藤光, 藤村響男ら: 強皮症患者の皮膚局所におけるサイトカインmRNA発現の検討. 強皮症調査研究班平成4年度研究報告書, pp66-70, 1993

• 12) 藤咲淳, 小池隆夫: 強皮症末梢血中のIL-6, 可溶性IL-6レセプターならびにgp130濃度. 強皮症調査研究班平成6年度研究報告書, pp120-123, 1994

• 13) 玉置邦彦, 玉木毅, 大西一徳ら: ヒト線維芽細胞におけるI型α2コラーゲン遺伝子の転写調節. 転写因子 Sp 1結合領域の役割. 強皮症調査研究班平成7年度研究報告書, pp26-33, 1995

• 14) 竹原和彦, 五十嵐敦之, 菊地かな子: 全身性強皮症組織におけるconnective tissue growth factor遺伝了の発現. 強皮症調査研究班平成6年度研究報告書, pp68-90, 1994

• 15) 橋本武則, 後藤秀樹, 谷口龍生ら: 全身性強皮症における肺線維症の経時的変化. 強皮症調査研究班平成4年度研究報告書, pp115-121, 1992

• 16) 鏑木淳一, 桑名正隆, 平形道人ら: 抗DNA topoisomerase I抗体陽性全身性強皮症の肺線維症と予後. 強皮症調査研究班平成5年度研究報告書, pp153-1258, 1993

• 17) 竹原和彦, 佐藤伸一, 菊地かな了ら: 全身性強皮症における抗ピストン抗体. 強皮症調査研究班平成4年度研究報告書, pp150-157, 1992

• 18) 林清二, 吉田光宏, 佐久間順子ら: TGF-β, PDGF-B, IL-6遺伝了導入によって誘導された間質性肺炎の異なった組織像. 強皮症調査研究班平成6年度研究報告書, pp78-83, 1994

• 19) Xing Z, et al: Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6induces lymphocytic hyperplacia in the lung. J Immunol 153: 4059-4069, 1994

• 20) 阿部達ら: 強皮症の疫学調査-life tableによる5年生存率. 厚生省強皮症, 皮膚筋炎および多発性筋炎調査研究班昭和49年研究業績総覧, pp19-23, 1974

• 21) Nishioka K, Katayama I, Kondo H, et al: Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis. J Dermatol 23: 677-682. 1996
  pubmed

• 22) 前田学, 松原勝利, 北島康雄ら: 岐阜県における最近5年間 (1987-1991年) の特定疾患診断書に基づいた全身性強皮症患者296例の予後調査. 強皮症調査研究班平成6年度研究報告書, pp179-185, 1994

• 23) 前田学, 川瀬晴美, 野間昭夫ら: 膠原病, 特に強皮症予備群における循環生理学的検査の有用性について. 強皮症調査研究班平成7年度研究報告書, pp136-142, 1995

• 24) 強皮症治療指針マニュアル. 厚生省特定疾患強皮症調査研究班編, 1994

• 25) 西岡清, 片山一朗, 近藤啓文ら: 全身性強皮症に伴うレイノー症状に対する薬物療法の評価. 強皮症調査研究班平成7年度研究報告書, pp248-257, 1995

• 26) 水谷仁, 稲地真, 清水由晴ら: 強皮症に対する経中心静脈的PGE, 長期持続注入療法. 強皮症調査研究班平成5年度研究報告書, pp182-185, 1993

• 27) 志水正敏,佐伯修, 林満寿彦ら: 二重膜式血漿濾過療法による強皮症の治療. 強皮症調査研究班平成5年度研究報告書, pp176-181, 1993

• 28) Hein R, Behr J, Hundgen M, et al: Treatment of systemic sclerosis with γ-interferon. Brit J Dermatol 126: 496-501, 1992

骨関節, 脊椎, 神経

P.85 掲載の参考文献

• 1) 総務庁統計局: 日本統計年鑑 (平成9年) . 日本統計協会, pp744-745, 東京, 毎日新聞社, 1996

• 2) Donohue JM, Buss D, Oegema TR, et al: The effects of indirect blunt trauma on adult canine articular cartilage. J Bone Joint Surg 65-A: 948-957, 1983
  pubmed

• 3) Vasan N: Effects of physical stress on the synthesis and degradation of cartilage matrix. Conn Tiss Res 12: 49-58, 1983

• 4) Aroskoski Y, Kiviranta I, Jurvelin J, et al: Long distance running causes site dependent decrease of cartilage glycosaminoglycan content in the knee joint of Beagle dog. Arthritis Rheum 36: 1451-1459, 1993

• 5) Lammi MY, Hakkinen TP, Parkkinen JJ, et al: Adaptation of canine femoral head articular cartilage to long distance running excercise in young beagles. Ann Rheum Dis 52: 369-377, 1993

• 6) Bennet GE: Shoulder and elbow lesions of the professional baseball pitcher. JAMA 117: 510-514, 1941

• 7) Adams JE: Injury to the throwing arm: a study of traumatic changes in the elbow joints of boy baseball players. California Med 102: 127-129, 1965

• 8) Bollen SR, Wright V: Radiographic changes in the hands of rock climbers. Br J Sports Med 28: 185-186, 1994
  pubmed

• 9) Vingard E, Alfredsson L, Goldie I, et al: Sports and osteoarthritis of the hip: an epidemiological study. Am J Sports Med 21: 195-200, 1993
  pubmed

• 10) Kujala UM, Kettunen J, Paananen H, et al: Knee osteoarthritis in former runners, soccer players, weight lifters and shooters. Arthritis Rheum 38: 539-546, 1995
  pubmed

• 11) Lindberg H, Roos H, Gardnall P: Prevalence of coxarthrosis in former soccer players: 286 players compared with matched controls. Acta Orthop Scand 64: 165-167, 1993
  pubmed

• 12) Roos H, Lindberg H, Gardsell P, et al: The prevalence of gonarthrosis in former soccer players and its relation to meniscectomy. Am J Sports Med 22: 219-222, 1994
  pubmed

• 13) Spector TD, Hattis PA, Hart DJ, et al: Risk of osteoarthritis associated with long-term weight-bearing sports: aradiologic survey of the hips and knees in fernale ex-athletes and population controls. Arthritis Rheum 39: 988-995, 1996

• 14) Lane NE, Michel B, Bjorkengren A, et al: The risk of osteoarthritis with running and ageing: a five ear longitudinal study. J Rheumatol 20: 461-468, 1993

• 15) Lane NE: Excercise: a cause of osteoarthritis. J Rheumatol 22 (Suppl): 3-6, 1995

• 16) Puranene J, Ala Ketola L, Peltokallio P, et al: Running and primary osteoarthritis of the hip. BMJ 2: 424-425, 1975
  pubmed

• 17) Sohn RS, Micheli L: The effect of running on the pathogenesis of osteoarthritis of the hips and knees. Clin Orthop 198: 1096-1098,1985

• 18) Panush RS, Schmidty C, Caldwell JT, et al: Is running associated with degenerativejoint disease? JAMA 255: 1152-1154, 1986

• 19) Marti B, Knobloch M, Tschopp A, et al: Is excessive running predictive of degenerative hip disease?: controlled study of former elite athletes, BMJ 299: 91-93, 1989
  pubmed

• 20) Konradsen L, Hansen BEM, Sondergaard L: Long distance running and osteoarthritis. Am J Sports Med 18: 379-381, 1990

• 21) Panush RS, Lane NE: Excercse and the musculoskeletal system. Baillere's Clin Rheumatol 8: 79-102, 1994

• 22) Williams JM, Brandt KD: Excercise increases osteophyte formation and diminishes fibrillation following chemically induced articular cartilage injury. J Anat 139: 599-611, 1984

• 23) Van Kampen GPJ, Veldhuijzen JP, Kuijer R, et al: Cartilage response to mechanical force in high-density chondrocyte cultures. Arthritis Rheum 28: 419-424, 1985

• 24) Eastmond CJ, Hudson A, Wright V: A radiological survey of the hips and knees in female specialist teachers of physical education. Scand J Rheumatol 8: 264-268, 1979

• 25) White JA, Wright V, Hudson AM: Relationships between habitual physical activity and asteoarthritis in ageing woman. Public Health 107: 459-470, 1993

P.93 掲載の参考文献

• 1) Schwarzer AC, et al: The relative contributions of the disc and zygapophyseal joint in chronic low back pain. Spine 19: 801-806, 1994

• 2) Bogduk N: The innervation of the lumbar spine. Spine 8: 286-293, 1983
  pubmed

• 3) Groen GJ, Baljet B, Drukker J: Nerves and nerve plexuses of the human vertebral column. Am J Anatomy 188: 282-296, 1990

• 4) 李芳祥ら: ラット腰椎後縦靱帯における侵害受容神経と交感神経の関わり. 日関外誌15: 187. 202, 1996

• 5) Takahashi Y, et al: Capsaicin applied to rat lumbar intervertebral disc causes extravasation in apossible mechanism of referred pain of the intervertbral disc. Neuroscience Letters 161: 1-3, 1993

• 6) Nakamura S, et al: The afferent pathways of discogenic low-back pain. Evaluation of L2 spinal nerve infiltration. J Bone Joint Surg 78-B: 606-612, 1996.

• 7) 大田寛, 小瀬弘一: 脊椎のalgodystrophy. リウマチ病セミナーIV (七川歓次監修), pp59-66, 大阪, 永井書店, 1993

• 8) Doury PC: The different types of reflex sympathetic dystrophy syndrome (algodystrophy). In: Bailliere's Clinical Orthopaedics Vol. 1 2nd issue, Reflex Sympathetic Dystrophy (Ed, Ficat CCJ), pp241-255, 1996

P.102 掲載の参考文献

• 1) Wilson AJ, Murphy WA, Hardy DC, et al: Transient osteoporosis: transient bone marrow edema? Radiology 167 (3): 757-760, 1988
  pubmed

• 2) Curtiss PH, Kincaid WE: Transitory demineralization of the hip in pregnancy: a report of three cases. J Bone Joint Surg[Am]4: 1324-1333, 1959

• 3) 久保俊一: 特発性一過性大腿骨頭萎縮症, 股関節の痛み (岩崎勝郎, 寺山和雄編集), pp170-176, 東京, 南江堂, 1998

• 4) Pantazopoulous T, Exarchou E, Hartofilakidis-Garofalidis G: Idiopathic transient osteoporosis of hip. J Bone Joint Surg[Am]55: 315-321, 1973

• 5) Bloem J: Transient osteoporosis of the hip: MR imaging. Radiology 167: 753, 1988
  pubmed

• 6) Potter H, Moran M, Schneider R, et al: Magnetic resonance imaging in diagnoses of transient osteoporosis of the hip. Clin Orthop 280: 223-229, 1992
  pubmed

• 7) Vande Berg B, Malghem J, Labaisse M, et al: MR imaging of avascular necrosis and transient marrow edema of the femaral head. Radiographics 13: 501-520, 1993

• 8) Hofmann S, Neuhold A, Leder K, et al: Bone-marrow edema syndrome and transient osteoporosis of the hip: An MRI-controlled study of treatment by core decompression. J Bone Joint Surg[Br]75: 210-216, 1993
  pubmed

• 9) 久保俊. .ら: Core biopsyを施行した特発性一過性大腿骨頭萎縮症の一例. 厚生省特定疾患特発性大腿骨頭壊死症調査研究班平成3年度報告書, pp37-45, 1992

• 10) Lequesne M: Transient osteoporosis of the hip: a nontraumatic variety of Sudeck's atrophy. Ann Rheum Dis 27: 463-471, 1968
  pubmed

• 11) McCord WC, Nies KM, Campion DS, et al: Regional migratory osteoporosis: a denervation disease. Arthritis Rheum 21: 834-838, 1978
  pubmed

• 12) Chan TW, Dalinka MK, Steinberg ME, et al: MRI appearance of femoral head osteonecrosis following core decompression and bone grafting. Skeletal Radiol 20: 103-107, 1991
  pubmed

• 13) Dunstan CR, Evans RA, Somers NM: Bone death in transient regional osteoporosis. Bone 13: 161-165, 1992
  pubmed

• 14) Kubo T, Yamazoe S, Sugano N, et al: Initial MRI findings of non-traumatic osteonecrosis of the femoral head in renal allograft recipients. Magn Reson Imaging 15: 1017-1023, 1997
  pubmed

• 15) Hays CW, Conway WF, Daniel WW: MR imaging of bone marrow edema pattern: transient osteonecrosis, transient bone marrow edema syndrome, or osteoporosis. Radiographics 13: 1001-1011, 1993
  pubmed

• 16) Mink JH, Deutsch AL: Occult cartilage and bone injuries of the knee: detection, classification, and assessment with MR imaging. Radiology 170: 823-829, 1989
  pubmed

• 17) Modic MT, Pflanze W, Feihlin DHI, et al: MRI of musculoskeletal infections. Radiol Clin North Am 24: 247-258, 1986

• 18) Richardson ML, Kilcoyne RF, Gillespy T, et al: Magnetic resonance imaging of musculoskeletal neoplasms. Radiol Clin North Am 24: 259-267, 1986
  pubmed

• 19) 久保俊一, 山本卓明, 居石克夫: 特発性大腿骨頭壊死症のMR画像と組織像. 整形外科48: 761-768, 1997

• 20) Koch E, Hofer HO, Sialer G, et al: Failure of MR imaging to detect reflex sympathetic dystrophy of the extremities. AJR 156: 113-115, 1991
  pubmed

P.112 掲載の参考文献

• 1) Mirra JM, Picci P, Gold RH: Bone Tumors. Philadelphia, Lea and Febiger, 1989

• 2) Unni KK: Dahlin's Bone Tumors. 5th Ed. Philadelphia, Lippincott-Raven, 1996

• 3) Dorfman HD, Czerniak B: Bone Tumors. St. Louis, Mosby, 1998

• 4) 大井憲二, 松本圭司, 西岡淳一ら: 大腿骨遠位骨幹端に発生したunusual osteosarcomaの1例. 整形外科 41: 799-802, 1990

• 5) Chano T, Matsumoto K, Ishizawa M, et al: Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various type of osteosarcomas. Eur J Histochem 40: 189-198, 1996

• 6) 森孝憲, 福田眞輔, 松本圭司ら: Periosteal Osteosarcomaの1例. 整形外科41: 1111-1114, 1990

• 7) Matsumoto K, Hukuda S, Ishizawa M, et al: Parosteal (Juxtacortical) chondrosarcorna of the humerus associated with regional lymph node metastasis. A case report. Clin Orthop 290: 168-173, 1993
  pubmed

• 8) Chano T, Matsumoto K, Ishizawa M, et al: Periosteal osteosarcoma and parosteal chondrosarcoma evaluated by double immunohistochemical staining. Report of 2 cases. Acta Orthop Scand 65: 355-358, 1994
  pubmed

• 9) Matsumoto K, Fukuda S, Ishizawa M, et al: Bizzare parosteal osteochondromatous proliferation (BPOP) of bone: Report of two cases treated with EHDP. Japanese J of Rheum and Joint Surg 16: 327-332, 1998

P.117 掲載の参考文献

• 1) Kellgren JH, Moore R: Generalized osteoarthritis and Heberden's nodes. Br Med J 1: 181-187, 1952

• 2) Kellgren JH, Lawrence JS, Bier F: Genetic factors in generalized osteoarthritis. Ann Rheum Dis 22: 237-255, 1963
  pubmed

• 3) Stecher RM: Heberden's nodes. Heredity in hypertrophic arthritis of the finger joints. Am J Med Sci 210: 801-809, 1941

• 4) Spector TD, Cicuttini F, Baker J, et al: Genetic influences on osteoarthritis in women: a twin study. Br Med J 312: 940-943, 1996

• 5) Felson DT, Couropmitree NN, Chaisson CE, et al: Evidence for a mendelian gene in a segregation analysis of generalized radiographic osteoarthritis. Arthritis Rheum 41: 1064-1071, 1998

• 6) Hirsch R, Lethbridge-Cejku M, Hanson R, et al: Familial aggregation of osteoarthritis. Data from the Baltimore longitudinal study on aging. Arthritis Rheum 41: 1227-1232, 1998
  pubmed

• 7) Brodsky A, Appelboom T, Govaerts A, et al: Antigenes HLA et nodosites d'Heberden. Acta Rhumatologica 3: 95-103, 1979
  pubmed

• 8) Pattrick M, Manhire A, Ward AM, et al: HLA-A, B antigens and α1-antitrypsin phenotypes in nodal generalized osteoarthritis and erosive osteoarthritis. Ann Rheum Dis 48: 470-475, 1989

• 9) Palotie A, Vaisanen P, Ott J, et al: Predisposition to familial osteoarthrosis linked to type II collagen gene. Lancet 1: 924-927, 1989
  pubmed

• 10) Knowlton RG, Katzenstein PL, Moskowitz RW, et al: Genetic linkage of a polymorphism in the type II procollagen gene (COL2A1) to primary osteoarthritis associated with a mild chondrodysplasia. N Eng J Med 322: 526-530, 1990

• 11) Priestley L, Fergusson C, Ogilvie D, et al: A limited association of generalized osteoarthritis with alleles at the type II collagen locus: COL2A1. Br J Rheumatol 30: 272-275, 1991
  pubmed

• 12) Meulenbelt I, Bijkerk C, Miedema HS, et al: Agenetic association study of the IGF-1 gene and radiological osteoarthritis in a population-based cohort study (the Rotterdam study) . Ann Rheum Dis 57: 371-374, 1998

• 13) Dequeker J: The relationship between osteoporosis and osteoarthrosis. Clin Rheum Dis 11: 271-295, 1985
  pubmed

• 14) Pogrund H, Rutenberg M, Makin M, et al: Osteoarthritis of the hip joint and osteoporosis: a radiological study in a random population sample in Jerusalem. Clin Orthop 164: 130-135, 1982

• 15) Solomon L, Schnitzler CM, Browett JP: Osteoarthritis of the hip: the patient behind the disease. Ann Rheum Dis 41: 118-125, 1982
  pubmed

• 16) 橋本淳: ビタミンDレセプター. リウマチ病セミナーIX (七川歡次監修), pp161-168, 大阪, 永井書店, 1998

• 17) Morrison NA, Qi JC, Tokita A, et al: Prediction of bone density from vitamin D receptor alleles. Nature 367: 284-287, 1994
  pubmed

• 18) Keen RW, Hart DJ, Lanchbury JS, et al: Association of early osteoarthritis of the knee with a Taq polymorphism of the vitamin D receptor gene. Arthritis Rheum 40: 1444-1449, 1997
  pubmed

• 19) Uitterlinden AG, Burger H, Huang Q, et al: Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J Clin Invest 100: 259-263, 1997
  pubmed

• 20) Tokita A, Matsumoto H, Morrison NA, et al: Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women. J Bone Miner Res 11: 1003-1009, 1996
  pubmed

• 21) Doherty M, Watt I, Dieppe T: Influence of primary generalized osteoarthritis on development of secondary osteoarthritis. Lancet 2: 8-11, 1983

• 22) Hall FC: Menopause arthralgia: study of 71 women at artificial menopase. N Eng J Med 219: 1015-1026, 1938

• 23) Stecher RM, Beard EE, Hersh AH: Heberden's nodes: the relationship of the menopause to degenerative joint disease of the fingers. J Lab Clin Med 34(2): 1193-1202, 1949

• 24) Spector TD, Campion GD: Generalized osteoarthritis: a hormonally mediated disease. Ann Rheum Dis 48: 523-527, 1989
  pubmed

• 25) Inoue K, Ushiyama T, Kim Y, et al: Increased rate of hysterectomy in women undergoing surgery for osteoarthritis of the knee. Osteoarthritis Cart 3: 205-209, 1995

• 26) Spector TD, Brown GC, Silman AJ: Increased rates of prior hysterectomy and gynaecological operations in women with osteoarthritis. Br Med J 297: 899-900, 1988

• 27) Ushiyalna T, Ueyama H, Inoue K, et al: Estrogen receptor gene polymorphism and generalized osteoarthritis. J Rheumatol 25: 134-137, 1998

• 28) Hill SM, Fuqua SAW, Chamness GC, et al: Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 49: 145-148, 1989

• 29) Kobayashi S, Inoue S, Hosoi T, et al: Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11: 306-311, 1996

検査法

P.129 掲載の参考文献

• 1) 荒木力編. はじめてのMRI-画像診断別冊KEY BOOKシリーズ, pp12-29, pp140 160, 東京, 秀潤社, 1995

• 2) アレン.D.エルスター: MRI「超」-講義-Q&Aで学ぶ原理と臨床応用 (荒木力監訳), pp100 119, pp186-213, 東京, 医学書院MYW, 1996

• 3) 多田信平: 誰にでもわかるMRI (荒木力編集), pp42-69, 東京, 秀潤社, 1995

• 4) Yao L, Lee JK: Occult intraosseous fracture: Detection with MR imaging. Radiology 167: 749-751, 1988
  pubmed

• 5) Mink JH, Deutsch A: Occult cartilage and bone injuries of the knee: Detection, classification, and assessment with MR imaging. Radiology 170: 823-829, 1989
  pubmed

• 6) Vahlensieck M, Lang P, Genant HK: The shoulder, In MRI of the musculoskeletal system (Ed, Chan WP, Lang P, Genant HK), pp188-189, Philadelphia, WB Saunders Company, 1994

• 7) Clyde A, Helms: 骨関節画像診断入門 (伊藤勝陽監訳), pp227-253, 東京, MBJ出版局, 1995

• 8) Lang P, Genant HK, Johnston JO: Musculoskeletal Neoplasm. In MRI of the musculoskeletal system (Ed, Chan WP, Lang P, Genant HK), pp401-443, Philadelphia, WB Saunders Company, 1994

P.137 掲載の参考文献

• 1) Steel DM, Whitehead AS: The major acute phase reactant: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15: 81-88, 1994
  pubmed

• 2) 奥田恭章, 高杉潔, 小山徹ら: 慢性関節リウマチに合併した2次性アミロイドーシス124例の臨床的検討-胃十二指腸生検による診断と予後を中心として-. リウマチ34: 939-946, 1994

• 3) 中野正明, 荒川止昭, 村澤章: 慢性関節リウマチにおける続発性アミロイドーシス. 臨床リウマチ9: 218-224, 1997

• 4) 中井秀紀, 尾崎承一, 狩野庄吾ら: 多施設研究による本邦の慢性関節リウマチに合併する続発性アミロイドーシスの臨床的特徴と遺伝的背景. リウマチ36: 25-33, 1996

• 5) Baba S, Takahashi T, Kasama T, et al: Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis. Biochim Biophys Acta 1180: 195-200, 1992

• 6) Baba S, Takahashi T, Kasama T, et al: A novel polymorphism of human serum amyloid A protein, SAA1γ, is characterized by alanines at both residues 52 and 57. Arch Biochem Biophys 303: 361-366, 1993

• 7) Baba S, Masago SA, Takahashi T, et al: A novel variant of serum amyloid A, SAalγ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4: 1083-1087, 1995

生物学的反応

P.146 掲載の参考文献

• 1) 越智隆弘, 田辺鎮雄, 藤本真弘ら: 同種胸腺細胞移植によるマウス多発関節炎における発症と増悪の要因. 臨床免疫23: 1419-1427, 1991

• 2) Hayashida K, Ochi T, Fujimoto M, et al: Bone marrow changes in adjuvant-induced and collagen induced arthritis. Interleukin-1 and interleukin-6 activity and abnormal myelopoiesis. Arthritis Rheum 35: 241-245, 1992
  pubmed

• 3) Ochi T, Hakomori S, Adachi M, et al: The presence of a myeloid cell population showing strong reactivity with monoclonal antibody directed to difucosyl type 2 chain in epiphyseal bone marrow adjacent to joints affected with rheumatoid arthritis (RA) and its absence in corresponding normal and non-RA bone marrow. J Rheumatol 15: 1609-1615, 1988
  pubmed

• 4) Tomita T, Kashiwagi N, Shimaoka Y, et al: Phenotypic characteristics of bone marrow cells in patients with rheumatoid arthritis. J Rheumatol 21: 1608-1614, 1994
  pubmed

• 5) Tomita T, Shimaoka Y, Kashiwagi N, et al: Enhanced expression of CD14 antigen on myeloid lineage cells derived from the bone marrow of patients with severe rheumatoid arthritis. J Rheumatol 24: 465-469, 1997
  pubmed

• 6) Wakitani S, et al: Elevated interleukin-1 levels in polymorphonuclear cells accumulating in bone marrow adjacent to affected joints in rheumatoid arthritis. Jpn J Rheumatol 5: 243-250, 1994

• 7) Hashimoto H, Tomita T, Hayashida K, et al: Expression and function of Fas antigen on bone marrow cells in patients with rheumatoid arthrits. Arthritis Rheum 39 (Supp1): S194, 1996

• 8) Wekerle H, et al: Thymic nurse cells-la-bearing epithelium involved in T-lymphocyte differentiation. Nature 283, 1980

• 9) 鈴木隆二, 豊崎朋子, 冨田哲也ら: リウマチ病変とナース細胞. リウマチ病セミナーVIII (七川歡次監修), pp155-163, 大阪, 永井書店, 1997

• 10) Tomita T, Takeuchi E, Maeda T, et al: Establishment of nurse-cell like stromal cell lines from bone marrow of patients with rheumatoid arthritis: characteristic bone marrow microenvironment of patients with rheumatoid arthritis (in submitting)

• 11) Takeuchi E, Tomita T, Maeda T, et al: Establishment and characterization of nurse cell-like stromal cell lines from synovial tissues of patients with RA. Arthritis Rheum (in press)

• 12) Nakagawa S, Toritsuka Y, Wakitani S, et al: Bone marrow stromal cells contribute to synovial cell proliferation in rats with collagen induced arthritis. J Rheumatol 23: 2098-2103, 1996
  pubmed

P.154 掲載の参考文献

• 1) Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs. Nature New Biol 231: 232-235, 1971

• 2) Sano H, Hla T, Maier JAM, et al: In Vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J CIin Invest 89: 97-107, 1992

• 3) Futaki M, Takahasi M, Yokoyama I, et al: NS-398, a new anti-inflammatory agent, selectively in hibits prostaglandin G.H synthase/cylooxygenase(COX-2) activity in vitro. Prostaglandins 47: 55-59, 1994

• 4) Futaki N, Yoshikawa K, Hamasaka Y, et al: NS-398, a novel non-steroidal antiinflammatory drug with protein analgesic and antipyretic effects, which cause minimal stomach lesions. Gen Pharmac 24: 105-110, 1993

• 5) 水野寿, 坂本長逸: Cox-2の病態における役割 4 胃潰瘍. 治療学30: 63-67, 1996

• 6) Reuter BK, Asfaha S, Bureta, et al: Exacerbation of inflammation associated colonic injury in rat through inhibition of cycooxygenase-2. J Clin Invest 98: 2076-2085, 1996

• 7) Kaufmann WE, Worley PF, Pegg J, et al: Cox-2, a synaptically induced enzyme, is expressed by excitatory neurons at post synaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93: 2317-2321, 1996

• 8) Slater DM, Berger LC, Newton R, et al: Expression of cyclooxygenase type 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 172: 77-82, 1995
  pubmed

• 9) Morham SG, Langenbach R, Loftin CD, et al: Prostaglandin synthase 2 gene disruption cause severe renal pathology in the mouse. Cell 83: 473-492, 1995
  pubmed

• 10) Laneuville O, Breuer DK, Dewitt DL, et al: Differential inhibition of human prostaglandin endoperoxide h synthase-1 and-2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271: 927-934, 1994
  pubmed

• 11) Henry D, Lim LLY, Rodriguez LAG, et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Brit Med J 312: 1563-1566, 1996

• 12) Prescott SM, White RL: Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87: 733-786. 1996

• 13) Oshima M, Dinchuk JE, Kargman SL, et al: Supression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (Cox-2) . Cell 87: 803-809, 1996

P.160 掲載の参考文献

• 1) Yonehara S, Ishii A, Yonehara M: Acell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor. J Exp Med 168: 1747-1756, 1989

• 2) Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991
  pubmed

• 3) Suda T, Takahashi T, Golstein P, et al: Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993
  pubmed

• 4) Ellis RE, Yuan J, Horvitz HR: Mechanism and functions of cell death. Annu Rev Cell Biol 7: 663-698, 1991
  pubmed

• 5) Alnemri ES, Livingston DJ, Nicholson DW, et al: Human ICE/CED-3protease nomenclature. Cell 87: 171, 1996

• 6) Yuan J, Shaham S, Ledoux S, et al: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β converting enzyme. Cell 75: 641-652, 1993

• 7) Thornberry NA, Bull HG, Calaycay JR, et al: A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356: 768-774, 1992

• 8) Nagata S: Apoptosis by death Factor. Cell 88: 355-365, 1997
  pubmed

• 9) Enari M, Sakahira H, Yokoyama H, et al: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50, 1998

• 10) Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317, 1992
  pubmed

• 11) Takahashi T, Tanaka M, Brannan CI, et al: Generalized lymphoproliferative disease in mice, caused by a point mutation in Fas ligand. Cell 76: 969-976, 1994
  pubmed

• 12) Fisher GH, Rosenberg FJ, Straus SE, et al: Dominant Interfering Fas genemutations impair apoptosis in a human autoimmune lymphoproliferative syndorome. Cell 81: 935-946, 1995

• 13) Rieux-Laucat F, Le Deist F, Hivroz C, et al: Mutations in Fas associated with human lymphoproliferative syndrorne and autoimmunity. Science 268: 1347-1349, 1995
  pubmed

• 14) Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995
  pubmed

• 15) Griffith TS, Brunner T, Fletcher SM, et al: Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192, 1995
  pubmed

P.168 掲載の参考文献

• 1) 金澤秀美, 清野佳起: ビタミンD不応症とビタミンD受容体異常. CLINICAL CALCIUM 7: 780-785, 1997

• 2) Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988
  pubmed

• 3) Brooks MH, et al: Vitamin-D-dependent rickets type II: resistance of target organs to 1, 25-dihydroxyvitamin D. N Engl J Med 298: 996-999, 1978
  pubmed

• 4) Marx SJ, et al: A familial syndrome of decrease in sensitivity to 1, 25-dyhydroxy vitamin D. J Clin Endocrinol Metab 47: 1303-1310, 1978

• 5) Hughes MR, Mallory PJ, Kieback DG, et al: Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242: 1702-1705, 1988

• 6) Morrison NA, Qi JC, Tokita A, et al: Prediction of bone density from vitamin D receptor alleles. Nature 367: 284-287, 1994
  pubmed

• 7) Peacock M: Vitamin D Receptor gene alleles and osteoporosis: a contrasting view. J Bone Min Res 10: 1294-1297, 1995

• 8) Yamagata Z, Miyamura T, Iijima S, et al: Vitamin D receptor gene polyrnorphism and bone mineral density in healthy Japanese women. Lancet 344: 1027, 1994
  pubmed

• 9) Tamai M, Yokouchi M, Koyama S, et al: Correlation between vitamin D receptor genotypes and bone mineral density in Japanese patients with osteoporosis. Calcif Tissue Int 60: 229-232, 1997

• 10) Arai H, Miyamoto K, Taketani Y, et al: A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women, J Bone Min Res 12: 915-921, 1997

• 11) Carling T, Kindmark A, Hellman P, et al: Vitamin D receptor genotype in primary hyperparathyroidism Nature Med 1: 1309-1311, 1995

• 12) Utterlinden AG, Burger H, Huang Q, et al: Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J CIin Invest 100: 259-264, 1997

• 13) Keen RW, Hart DJ, Lanchbury JS, et al: Association of early osteoarthritis of the knee with a Taq I polymorphism of vitamin D receprtor gene. Arthritis Rheumatism 40: 1444-1449, 1997
  pubmed

• 14) 牛山敏夫: genetic markerとOA, リウマチ病セミナー (七川歡次監修), p280-285, 大阪, 永井書店, 1998

• 15) Matsuyama T, Ishii S, Tokita A, et al: Vitamin D receptor genotype and bone mineral density. Lancet 345: 1238-1239, 1995
  pubmed

P.184 掲載の参考文献

• 1) Matsushima K, Morishita K, Yoshimura T, et al: Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 167: 1883-1893, 1988
  pubmed

• 2) 向田直史: ケモカインと感染. 感染炎症免疫 27: 152, 1997

• 3) Holmes WE, Lee J, Kuang WJ, et al: Structure and functional expression of a human interleukin-8 receptor. Science 253: 1278-1280, 1991

• 4) Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253: 1280-1283, 1991

• 5) Matsushima K, Larsen CG, DuBois GC, et al: Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169: 1485-1490, 1989
  pubmed

• 6) Yoshimura T, Robinson EA, Tanaka S, et al: Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169: 1449-1459, 1989
  pubmed

• 7) Rathanaswami P, Hachicha M, Sadick M, et al: Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines, J Biol Chem 268: 5834-5839, 1993
  pubmed

• 8) Zipfel PF, Balke J, Irving SG, et al: Mitogenic activation of human T cells induces two closely related genes which share structural similarities with a new family of secreted factors. J Immunol 142: 1582-1590, 1989

• 9) Koch AE, Kunkel SL, Harlow LA, et al: Macrophage inflammatory protein 1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arhtiritis. J Clin Invest 93: 921-928, 1994

• 10) Vieira P, de Waal Malefyt R, Dang MN, et al: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc Natl

• 11) Liu Y, Wei SH, Ho AS, et al: Expression cloning and characterization of a human IL-10 receptor. J Immunol 152: 1821-1829, 1994

• 12) Wolf SF, Temple PA, Kobayashi M, et al: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991

• 13) Chua AO, Chizzonite R, Desai BB, et al: Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 158: 128, 1994

• 14) Grabstein KH, Eisenman J, Shanebeck K, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264: 965-968, 1994

• 15) Carson WE, Giri JG, Lindemann MJ, et al: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395-1403, 1994
  pubmed

• 16) McInnes IB, al Mughales J, Field M, et al: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nature Med 2: 175-182, 1996

• 17) Thurkow EW, van der Heijden IM, Breedveld FC, et al: Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 181: 444-450, 1997
  pubmed

• 18) Al-Mughales J, Blyth TH, Hunter JA, et al: The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin exp Immunol 106: 230-236, 1996
  pubmed

• 19) Baier M, Bannert N, Werner A, et al: Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Ntl Acad Sci USA 94: 5273-5277, 1997

• 20) Zhang YJ, Center DM, Wu DMH, et al: Processing and activation of pro-interleukin-16 by caspase 3. J Biol Chem 273: 1144-1149, 1998

• 21) Rumsaeng V, Cruikshank WW: Human mast cells produce the CD 4 (+) T lymphocyte chemoattractant factor, IL-16. J Immunol 159: 2904-2910, 1997

• 22) Lim KG, Wan HC, Bozza PT, et al: Human eosinophils elaborate the lymphocyte chemoattractants IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 156: 2566-2570, 1996
  pubmed

• 23) Parada NA, Center DM, Kornfeld H, et al: Synergistic activation of CD 4 (+) Tcells by IL-16 and IL-2. J Immunol 160: 2115-2120, 1998

• 24) Krautwald S: IL-16 activates the SAPK signaling pathway in CD 4 (+) macrophages. J Immunol 160: 5874-5879, 1998

• 25) Zhou P, Goldstein S, Devadas K, et al: Human CD 4 +cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression. Nature Med 3: 659-664, 1997

• 26) Fossiez F, Djossou O, Chomarat P, et al: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593-2603, 1996
  pubmed

• 27) Yao ZB, Spriggs MK, Derry JMJ, et al: Molecular characterization of the human interleukin (IL)-17receptor. Cytokine 9: 794-800, 1997

• 28) Chabaud M, Fossiez F, Taupin JL, et al: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th 2 cytokines. J Immunol 161: 409-414, 1998

• 29) Jovanovic DV, Dibattista JA, MartelPelletier J, et al: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1 beta and TNF-alpha, by human macrophages. J Immunol 160: 3513-3521, 1998

• 30) Okamura H, Tsutsui H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-γproduction by T cells. Nature 378: 88-91, 1995

• 31) Ushio S, Namba M, Okura T, et al: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156: 4274-4279, 1996

• 32) Udagawa N, Horwood NJ, Elliott J, et al: Interleukin-18 (inferferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 185: 1005-1012, 1997

• 33) Gu Y, Kuida K, Tsutsui H, et al: Activation of interferon-γinducing factor mediated by interleukin-1β converting enzyme. Science 275: 206-209, 1997

• 34) Ghayur T, Banerjee S, Hgunin M, et al: Caspase-1 processes IFN-γ-inducing factor and regulates ILS-induced IFN-γproduction. Nature 386: 619-623, 1997

• 35) Tone M, Thompson SA, Tone Y, et al: Regulation of IL-18 (IFN-γ-inducing factor) gene expression. J Immunol 159: 6156-6163, 1997

• 36) Conti B, Jahng JW, Tinti C, et al: Induction of interferon-γinducing factor in the adrenal cortex. J Biol Chem 272: 2035-2037, 1997

• 37) Tsutsui H, Matsui K, Kawada N, et al: IL-18 accounts for bdth TNF-α-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 159: 3961-3967, 1997

• 38) Matsui K, Yoshilnoto T, Tsutsui H, et al: Propionibacterium acnes treatment diminishes CD 4 + NK1. 1+T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 159: 97-106, 1997

• 39) Bazan JF: Strutural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 87: 6934-6938, 1990

• 40) Premack BA, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nature Medicine 11: 1174-1178, 1996
  pubmed

P.193 掲載の参考文献

• 1) Truss M, Beato M: Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14: 459-479, 1993
  pubmed

• 2) 上野晃憲: アラキドン酸代謝物と炎症. 炎症と免疫 3: 21-28, 1995
  Medical*Online

• 3) Flower RJ: Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol 94: 987-1015, 1988
  pubmed

• 4) Goppelt-Struebe M: Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 53: 1389-1395, 1997
  pubmed

• 5) Diamond MI, Miner JN, Yoshinaga SK, et al: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249: 1266-1272, 1990
  pubmed

• 6) Jonat C, Rahmsdorf HJ, Park K-K, et al: Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62: 1189-1204, 1990
  pubmed

• 7) Vacca A, Felli MP, Farina AR, et al: Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175: 637-646, 1992

• 8) Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752-756, 1994

• 9) Mukaida N, Morita M, Ishikawa Y, et al: Novel mechanism of glucocorticoid-mediated gene repression: NF-κB is target for glucocorticoid-mediated IL-8 gene repression. J Biol Chem 269: 13289-13295, 1994

• 10) Caldenhoven E, Liden J, Wissink S, et al: Negative cross-talk between Re1A and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9: 401-412, 1995

• 11) Brostjan C, Anrather J, Csizmadia V, et al: Glucocorticoids inhibit E-selectin expression by targeting NF-κB and not ATF/c-Jun. J Immunol 158: 3836-3844, 1997

• 12) Scheinman RI, Cogswell PC, Lofquist AK, et al: Role of transcriptional activation of Iκ Bαin mediation of immunosuppression by glucocorticoids. Science 270: 283-286, 1995

• 13) Auphan N, Didonato JA, Rosette C, et al: Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270: 286-290, 1995

• 14) Brostjan C, Anrather J, Csizmadia V, et al: Glucocorticoid-mediated repression of NF-KB actiivity in endothelial cells does not involve induction of IK B αsynthesis. J Biol Chem 271: 19612-19616, 1996

• 15) Heck S, Bender K, Kullmann M, et al: IκB α-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J 16: 4698-4707, 1997

• 16) Vervoordeldonk MJBM, Schalkwijk CG, Pfeilschifter J, et al: Effects of dexamethasone and transforming growth factor-β2 on group II phospholipase A2 mRNA and activity levels in interleukin-1β-and forskolin-stimulated mesangial cells. Biochem J 315: 435-441, 1996

• 17) Gewert K, Sundler R: Dexamethasone down-regulates the 85 KDa phospholipase A 2 in mouse macrophages and suppresses its activation. Biochem J 307: 499-504, 1995
  pubmed

• 18) Ristimaki A, Narko K, Hla T: Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318: 325-331, 1996
  pubmed

治療と副作用

P.206 掲載の参考文献

• 1) Merskey H, Bogduk N: Classification of chronic pain. IASP Press, 1994

• 2) Roberts WJ: A hypothesis on the physiological basis for causalgia and related pains. Pain 34: 289-304, 1988

• 3) Meller ST, Gebhart GF: Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 52: 127-136, 1993.
  pubmed

• 4) Bonica JJ: Causalgia and other reflex sympathetic dystrophies. In: The Management of Pain (Ed, Bonica JJ) pp220-243, Philadelphia, Lea and Febiger, 1990

• 5) Raja SN, Treede R-D, Davis KD, et al: Systemic alpha adrenergic blockade with phentolamine; A diagnostic test for sympathetically maintained pain. Anesthesiology 74: 691-698, 1991
  pubmed

• 6) Hannington-Kiff JG: Relief of Sudeck: s atrophy by regional intravenous guanethidine. Lancet 1: 1132-1133, 1977
  pubmed

• 7) 真下節, 富勝治, 朴銘ら: 局所静脈内グネアチジン投与による四肢の反射性交感神経性萎縮症の治療経験.ペインクリニック 7: 458-462, 1986

• 8) Mashimo T, Pak M, Inagaki Y, et al: Effects of intravenous regional administration of vasodilators; guanethidine, nicardipine, nitroglycerine and prostaglandin E1 in a patient with causalgia. The Pain Clinic 8: 255-261, 1995

• 9) Shimoji K, Kitamura H, Ikezono E, et al: Spinal hypalgesia and analgesia by low-frequency electrical stimulation in the epidural space. Anesthesiology 41: 91-94, 1974
  pubmed

• 10) Tsubokawa T, Katayama Y, Yamamoto T, et al: Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg 78: 393-401, 1993

P.213 掲載の参考文献

• 1) Warren JR, Marshall B: Unidentified curved bacilli on gastiric epithelium in active chronic gastritis. Lancet 1: 1273-1275, 1983

• 2) Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315, 1984
  pubmed

• 3) Tomb JF, White O, Kerlavage AR, et al: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547, 1997
  pubmed

• 4) Cover TL, Blaser MJ: Purification and characterization of the vacuolating from Helicobacter pylori. J Biol Chem 267: 10570-10575, 1992
  pubmed

• 5) 山本一成, 福田能啓, 奥井雅憲ら: 抗菌剤と潰瘍薬のH. pylori菌に対する感受性. 綜合臨牀 10: 2513-2520, 1997
  Medical*Online

P.222 掲載の参考文献

• 1) Paulus HE: The use of combination of disease-modifying antirheumatic agent in rheumatoid arthritis. Arthritis Rheum 32: 113-120, 1990

• 2) Paulus HE: History of combination therapy of rheumatoid arthritis. J Rheumatol 23 (Suppl): 38-42, 1996

• 3) Siever K, Hurri L: Combined therapy of rheumatoid arthritis with gold and chloroquine. Acta Rheuma Scand 9: 4-55, 1963

• 4) Lockie LM, Norass BM: Salicylate, phenyl butazone, chloroquine and indomethacin in treatment of rheumatoid arthritis: Arthritis&allied condition (Ed, Hollander JR), pp338-348, Philadelphia, Lea & Febiger, 1996

• 5) McCarty DJ, Carrera GF: Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathiopurine, and hydroxychloroquine. JAMA 248: 1718-1723, 1982

• 6) Martin M, Dixon J, Hickling P, et al: Acombination of D-penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis (abst), Ann Rheum Dis 41: 208, 1982

• 7) Siegleton PL, Cervantes AG: Concomitant gold and hydroxychloroquine of second remission of rheumatoid arthritis (abst), Meeting of the Southeast Asia and Pacific Area league Against Rheumatism, Bangkok, Thailand, 1984

• 8) Bitter T: Combined disease-modifying chemotherapy for intractable rheumatoid arthritis. Rheum Dis Cli North Am 10: 413-428, 1984.

• 9) Bunch TW, O: Duffy JD, Tompkins RB, et al: Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 27: 267-276, 1984

• 10) McKenne F, Hopkins RB, Hinchcliffe KP, et al: Gold and penicillamine, alone and in combination in active rheumatoid arthritis (abst). 16th International Congress of Rheumatology, Sydney, Australia, 1983

• 11) Gibson T, Emery P, Armstrong RD, et al: Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis: A comparative study. Br J Rheumatol 26: 279-284, 1987
  pubmed

• 12) Scott DL, Dawes PL, Tunn E, et al: Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis. Br J Rheumatol 7: 128-133, 1988

• 13) Farr M, Kitas G, Bacon PA: Sulfasalazine in rheumatoid arthritis: Combination therapy with D-penicillamine or sodium autothiomalate. Clin Rheumatol 7: 242-248, 1988

• 14) Taggart AJ, Hill J, Asbury C, et al: Sulfasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol 26: 32-36, 1987
  pubmed

• 15) Brawer AE: The combined use of methotrexate and intramuscular gold in rheumatoid arthritis (abst). Arthritis Rheum 8 (Suppl): S10, 1988

• 16) Wilke WS, Sherrer YR, Clough JD: Combination chemotherapy for severe rheumatoid arthritis. IM-Internal Medicine for the Specialist 10: 59-76, 1989

• 17) Tiliakos HA: Low dose cytotoxic drug combination therapy in intractable rheumatoid arthritis: two years later (abst) . Arthritis Rheum 29 (Suppl): S 79, 1986

• 18) Fries JF: Reevaluating the therapeutic approach to rheumatoid arthritis. "the Sawtooth"strategy. J Rheumatol (Suppl) 22: 17: 12-15, 1990

• 19) Bensen WG, Benson E, Adachi JO: Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis. J Rheumatol 21: 2034-2038, 1994

• 20) Tugwell DT, Pincus T, Yocum D, et al: Combination therapy with cyclophosphamide and methotrexate in severe rheumatoid arthritis. New Engl J Med 333: 127-141, 1995

• 21) Luthra HS: Midwest Cooperative Rheumatic DISEASE Study Group: Double-blined study comparing auranofin and hydroxychloroquine alone and in combination in rheumatoid arthritis: Acontrolled trial. Arthritis Rheum 33 (Suppl): S25, 1990

• 22) Wiliams HJ, Ward JR, Reading JC, et al: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: A controlled trial. Arthritis Rheum 32: 259-269, 1992

• 23) Clegg DO: HCO Study Group: Combination hydroxychloroquine and methotrexate in the treatment of rheumatoid arthritis (abst) . Arthritis Rheum 33 (Suppl): S53, 1993

• 24) Faarvang KL, Egsmose C, Kryger P, et al: Hydroxychloroquine and sulfasalazine alone and in combination in rheumatoid arthritis: A Rheum Dis 52: 711-715, 1993
  pubmed

• 25) Tugwell P: Combination therapy in rheumatoid arthritis: Methaanalysis. J Reumatol 23 (Suppl): 43-46, 1996

• 26) O'Dell JR, Haire CE, Erikson N, et al: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or combination of all three medications. New Engl J Med 334: 1287-1291, 1996
  pubmed

• 27) O'Dell J: Combination DMARD therapy for rheumatoid arthritis: a step close to the goal. Ann Rheum Dis 55: 781-782, 1996

• 28) 延永正: 寛解導入剤 (DMARD) の併用療法. リウマチ34: 88-98, 1994

• 29) Morland LW, Kimberly RP, Alarcon GS: Europian (EU) and US Rheumatol ogist (Rheum) agree in triple not on double or single early DMARD choice for different types of rheumatoid arthritis. Arthritis Rheum 24 (Suppl): S1125, 1997

• 30) Roger L, Masi AT, Luther M: High clinical remission rates following early therapy of active rheumatoid arthritis with aurothioglucose and low-dose triamcinolone. Arthritis Rheum 24 (Suppl): S126, 1997

• 31) Tim G, La Montagna G, Salaffi F, et al: Combination therapy with cyclosporin and hydroxychloquine in early active severe rheumatoid arthritis. Arthritis Rheum 24 (Suppl): S397, 1997

• 32) Grunke M, Lorenz HM, Hieronymus T, et al: Combination therapy in rheumatoid arthritis: In vitro evaluation of combinations of established DMARD and immunologic agents. Arthritis Rheum 24 (Suppl): S982, 1997

• 33) Yocum DE, Nordensson K, Gatherers L: Combination cyclosporin plus methotrexate: Immnologic effects over 18 months of therapy. Arthritis Rheum 24 (Suppl): S976, 1997

• 34) Leirisalo-Repo M, Kautiainen LH: Safty DMARD combination therapy to single drug treatment in early rheumatoid arthritis. Arthritis Rheum 24 (Suppl): S122, 1997

• 35) O'Dell J;Combination DMARD therapy for rheumatoid arthritis: apparent universal acceptance. Arthritis Rheum 24 (Suppl): S119, 1997

• 36) Weinblatt ME, Kremer GM, Coblyn JS, et al: Leflunomide plus methotrexate on refractory rheumatoid arthritis: a pilot study. Arthritis Rheum 24 (Suppl): S974, 1997

• 37) Haagsma C, Blom H, van Riel, et al: The influence of sulfasalazine, methotrexate and the combination of both on plasma homocysteen levels on patients with rheumatoid arthritis. Arthritis Rheum 24 (Suppl): S118, 1997

• 38) Hemandez-Garcia C, Jover JA, Banares A, et al: Analysis of indications, efficasy and safety of combination therapy in rheumatoid arthritis patients unresponsive to single therapy. Arthritis Rheum 24 (Suppl): S120, 1997

• 39) van Gestel AM, van Riel PCLM, van de Putte: Drug survival of sulfasalazine and rnethotrexate: single versus combination. Arthritis Rheum 24 (Suppl) S969, 1997

• 40) Ferracioli GE, Di Poi E, Damato R, et al: Analysis of remission and full responses in rheumatoid arthritis treated with cornbination therapy for three years. Arthritis Rheum 24 (Suppl): S1129, 1997

• 41) Bico JC, Verhoeven AC, Boers M, et al: Cobra combination therapy is cost-effective in early rheumatoid srthritis. Arthritis Rheum 24 (Suppl): S1771, 1997

• 42) Nissila M, Lassonen L, Leirisalo-Repo M: Supeiority of DMARD combination therapy to single drug treatment strategy in early rheumatoid arthritis.: progression of structual joint damage. Arthritis Rheum 24 (Suppl): S117, 1997

• 43) Leirisalo-Repo M, Kautiainen H: Safety of DMARD combination therapy to single drug treatment in early rheumatoid arthritis, Arthritis Rheum 24 (Suppl): S122, 1997

• 44) Mottinen T, Hannonen P, Korpela M, et al: Superiority of DMARD combination therapy to single drug treatment strategy in rheumatoid arthritis. Arthritis Rheum 24 (Suppl): S1128, 1997

• 45) Bensen WG, Bensen E, Adachi JO: Back to the future: the pyramid of rheumatoid arthritis. J Rheumatol 24: 1023-1027, 1997

• 46) Furst DE: Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. J Rheumatol 23 (Suppl): 486-490, 1996

• 47) Sokka TM, Kautiainen HJ, Hannonen PJ: Aretrospective study of treating rheumatoid arthritis patients with various combination of slow-acting anti-rheumatic drugs in country hospital. Scand J Rheumatol 26: 440-443, 1997

• 48) Wilske KR, Yocum DE: Rheumatoid arthritis: The status and future of combination therapy. J Rheumatol 23 (Suppl): 110, 1996

• 49) Strand V: The future use of biologic therapies in combination for the treatment of rheumatoid arthritis. J Rheumatol 23 (Suppl): 91-96, 1996

• 50) Faccioli GF, Bartoi E: Combination DMARD therapy for rheumatoid arthritis: full or low DMARD dosis, Ann Rheum DIS 56: 336-338, 1997

• 51) Salmon SE, Dalton WS: Relevance of multidrug to rheumatoid arthritis: developement of a new therapeutic hypothesis. J Rheumatol 23 (Suppl): 97-101, 1996

• 52) Yelin E: The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimate. J Rheumatol 23 (Suppl): 47-54, 1996

• 53) Dukmans BAC, van den Borne BEEM, Landewe RBM, et al: Chloroquine combined with cyclophosphamide in rheumatoid arthritis: more than the addition of 2 drugs alone. J Rheumatol 23 (Suppl): 61-63, 1976

• 54) Clegg DO, Dietz F, Duffy J, et al: Safty and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24: 1896-1902, 1997

• 55) Situnayaka RD, Kitas G: Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56: 341-342, 1997

• 56) Mururo R, Morrison E, McDonald AG, et al: Effect of disease modyfying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56: 374-377, 1997

P.234 掲載の参考文献

• 1) Gubner R, August S, Ginsberg V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 22: 176-182, 1951

• 2) O'Dell JR: Methotrexate use in rheumatoid arthritis. In Rheumatic Disease Clinics of NorthAmerica, "Methotrexate" (Ed, Joseph M, Cash MD) pp779-796, Philadelphia, WB Saunders, 1997

• 3) Thompson RN, Watts C, Edelman J, et al: A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11: 760-762, 1984

• 4) Anderson PA, West SG, O'dell JR, et al: Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 103: 489-496, 1985

• 5) Williams HJ, Wilkens RF, Samuelson CO, et al: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis-a controlled clinical trial, Arthritis Rheum 28: 721 729, 1985

• 6) Weinblatt ME, Cobby JS, Fox DA, et al: Efficacy of low dose methotrexte in rheumatoid arthritis. N Engl J Med 312: 818-822, 1985

• 7) Kremer JM, Phelps CT: Long-term prospetive study of the use of methotrexate in the treatment of rheumatoid arthritis: Update after a mean of 90 months. Arthritis Rheum 35: 138-145, 1992

• 8) Weinblatt ME, Weissman BN, Holdsworth DE, et al: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-months update. Arthritis Rheum 35: 129-137, 1992
  pubmed

• 9) Pincus T, Marcum SB, Callahan LF: Long-term drug therapy for rheumatoid arthritis in seven Rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 19: 1885-1894, 1992

• 10) Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Clin Rheumatol 9: 619-632, 1995
  pubmed

• 11) Alarcon GS, Tracy IC, Blackburn WD Jr: Methotrexate in rheumatoid arthritis: Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32: 671-676, 1989
  pubmed

• 12) Suarez-Almazor ME, Fitzgerald A, Grace M, et al: A randomaized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine R) in the treatment of rheumatoid arthritis. J Rheumatol 15: 753-756, 1988

• 13) Morassut P, Goldstein R, Cyr M, et al: Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized double blind 26-week trial. J Rheumatol 16: 302-306, 1989

• 14) Hamdy H, McKendry RJR, Mierins E, et al: Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthritis Rheum 30: 361-368, 1987

• 15) Weinblatt ME, Trentham DE, Fraser PA, et al: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis, Arthritis Rheum 31: 167-175, 1988
  pubmed

• 16) Weinstein A, Marlowe S, Korn J, et al: Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am J Med 79: 331-337, 1985
  pubmed

• 17) Kremer JM, Lee JK, et al: A long term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months. Arthritis Rheum 31: 577-584, 1988
  pubmed

• 18) Situnayake RD, Grindulis KA, McConkey B: Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table method. Ann Rheum Dis 46: 177-183, 1987
  pubmed

• 19) Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17: 994-1002, 1990
  pubmed

• 20) 市川陽一, 篠沢妙子, 吉田正ら: 慢性関節リウマチにおけるメトトレキサート療法の問題点・リウマチ 31: 544-553, 1991

• 21) Segal R, Yaron M, Tartakovsky B: Methotrexate: Mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 20: 190-200, 1990
  pubmed

• 22) 谷口敦夫, 中島亜矢子, 箱田雅之ら: 慢性関節リウマチにおけるメトトレキサートの作用機序 リウマチ病セミナーVII (七川歡次監修) pp216-223, 大阪, 永井書店, 1996

• 23) Morgan SL, Hine RJ, Vaughn WH, et al: Dietary intake and circulating vitamin levels of rheumatoid arthritis patients treated with methotrexate. Arthritis Care and Research 6: 4-10, 1993
  pubmed

• 24) Morgan SL, Baggot JF, Vaughn WH, et al: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 9-18, 1990

• 25) Leeb BF, Witzmann G, Ogris E, et al: Folic acid and cyanocobalamin levels in serum and erythrocyte during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 13: 459-463, 1995
  pubmed

• 26) Morgan SL, Baggot JE, Vaughn WH, et al: Supplementaion with folic acid during methotrexate therapy for rheumatoid arthritis, A double-blind, placebo-controlled trial. Ann Intern Med 121: 833-841, 1994

• 27) Stewart KA, Mackenzie AH, Clough JD, et al: Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum 20: 332-338, 1991
  pubmed

• 28) Jobanputra P, Hunter M, Clark D, et al: An audit of methotrexate and folic acid for rheumatoid arthritis. experience from a teaching centre. Br J Rheumatol 34: 971-975, 1995
  pubmed

• 29) Hanrahan PS, Scrivens GA, Russell AS: Prospective long term follow up of methotrexate therapy in rheumatoid arthritis, efficacy and radiological progression. Br J Rheumatol 28: 147-153, 1989
  pubmed

• 30) Buchbinder R, Hall S, Sambrook PN, et al: MTX therapy in rheumatoid arthritis: a life table reviews of 587 patients treated in community practice, J Rheumatol 20: 639-644, 1993

• 31) Tisler M, Capsi D, Fishel B, et al: The effect of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients, Arthritis Rheum 31: 906-908, 1988

• 32) Joyce DA, Will RK, Hoffman DM, et al: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 50: 913-914, 1991
  pubmed

• 33) Hanrahan PS, Russell AS: Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 15: 1078-1080, 1988
  pubmed

• 34) Shiroky JB: The use of folates concomitantly with low-dose pulse methotrexate. In Rheumatic Disease Clinics of North America, "Methotrexate" (Ed, Joseph M, Cash MD) pp969-980, Philadelphia, WB Saunders, 1997

• 35) Buckley LM, Vacek PM, Cooper SM: Administration of folinic acid after low dose Inethotrexate in patients with rheumatoid arthritis. J Rheumatol 17: 1158-1161, 1990
  pubmed

• 36) Shiroky JB, Neville C, Esdaile JM, et al: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 36: 795-803, 1993
  pubmed

• 37) Weinblatt ME, Maier AL, Coblyn JS: Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 20: 950-952, 1993
  pubmed

• 38) Segal AM, Wilke WS: Toxicity of low-dose methotrexate in rheumatoid arthritis, In Methotrexate Therapy in Rheumatic disease (Ed. Wilke WS). New York, NY, Mercel Decker, 1989

• 38) American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39: 723 731, 1996

• 39) Alarcon GS, Morgan SI: Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: comment on the guidelines for monitoring drug therapy. Arthritis Rheum 40: 391, 1997

• 40) van Ede AE, Laan RFJM, Blom HJ, et al: Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27: 277-292, 1998

P.246 掲載の参考文献

• 1) 菊地臣一, 星加一郎, 奥津一郎ら: 機能的診断法としての神経根ブロック-局所解剖的, 臨床的検討-. 整形外科33: 289-297, 1982

• 2) Hasue M, Kikuchi S, Sakuyama Y, et al: Anatomic study of the interrelation between lumbosacral nerve roots and their surrounding tissues. Spine 8: 50-57, 1983
  pubmed

• 3) 松井達也, 菊地臣一, 星加一郎ら: 腰仙部神経根症状に関する神経根ブロックの治療効果. 臨整外 20: 1019-1026, 1985

• 4) Macnab I: Negative disc exploration. An analysis of the causes of nerve-root involvement in sixty-eight patients. J Bone Joint Surg 53-A: 891-903, 1971
  pubmed

• 5) Dooley JF, McBroom RJ, Taguchi T, et al: Nerve root infiltration in the diagnosis of radicular pain. Spine 13: 79-83, 1988
  pubmed

• 6) Stanley D, McLaren MI, Euinton HA, et al: A prospective study of nerve root infiltration in the diagnosis of sciatica. A comparison with radiculography, computed tomography, and operative findings. Spine 15: 540-543, 1990
  pubmed

• 7) Derby R, Kine G, Saal J, et al: Response to steroid and duration of radicular pain as predictors of surgical outcome. Spine 17: s176-s183, 1992

• 8) Olmarker K, Rydevik B, Holm S: Edema formation in spinal nerve roots induced by experimental, graded compression. An experimental study on the pig cauda equina with special reference to differences in effects between rapid and slow onset of compression. Spine 14: 569-573, 1989

• 9) Hoyland J, Freemont AJ, Jayson MIV: Intervertebral foramen venous obstruction. A cause of periradicular fibrosis? Spine 14: 558-568, 1989

P.250 掲載の参考文献

• 1) Ikehara S: The prospects for BMT; from mouse to human. In Bone Marrow Transplantation: Basic and Clinical Studies (Ed, Ikehara S, Takaku F, Good RA), pp302-331, Tokyo, Springer-Verlag, 1996

• 2) Sullivan KM, Furst DE (Eds): Role of hernatopoietic stem cell transplantation for autoimmune diseases. J Rheumatol 24 (suppl 48): 1-102, 1997

• 3) 日本造血細胞学会平成8年度全国調査報告書-成人での造血細胞移植. 全国データ集計事務局, 平成8年12月

P.259 掲載の参考文献

• 1) Riggs BL, Melton LJIII: Involutional osteoporosis. N Engl J Med 314: 1676-1686, 1986
  pubmed

• 2) Carnero P, Shih WJ, Gineyts E, et al: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 1693-1700, 1994

• 3) Marcus R, Madvig P, Young G: Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans. J Clin Endocrinol Metab 58: 223-230, 1984
  pubmed

• 4) 中塚喜義, 森井浩世: 骨粗鬆症の概念と分類. 最新内科学体系骨疾患 (坂根剛, 森井浩世編), pp129-138, 東京, 中山書店, 1995

• 5) Riggs BL: Overview of osteoporosis. West J Med 154: 63-77, 1991
  pubmed

• 6) Frost M: Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 3: 211-237, 1969

• 7) Kanis JA: Maintenance of bone mass. Textbook of osteoporosis (Ed, Kanis JA), pp22-55, Oxford, Blackwell Science, 1994

• 8) 中村利孝: 高齢者の骨代謝, 形態面からみた骨代謝. Bone 9: 29-34, 1995

• 9) 上好昭孝, 大田喜一郎: 閉経後骨粗鬆症のカルシウム代謝調節ホルモンについて. 骨粗鬆症研究の進歩-基礎と臨床-6: 91-97, 1991

• 10) Parfitt AM, Chir MBB: Trabecular bone architecture in the pathogenesis and prevention of fracture, Am J Med82: 68-72, 1987

• 11) Slovic DM, Adams JS, Neer RM, et al: Deficient production of 1, 25-dehydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305: 372-374, 1981

• 12) Gallagher JC, Riggs BL, Eisman J, et al: Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: Effect of age and dietary calcium. J CIin Invest 64: 729-736, 1979

• 13) Francis RM, Peacock M, Taylor GA, et al: Calcium malabsorption in elderly women with vertebral fractures: evidence for resistance to the action of vitamin D metabolites on the bowel, Clin Sci 66: 103-107, 1984

• 14) Cooper GS, Umbach DM: Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 11: 1841-1849, 1996
  pubmed

• 15) 金木正夫: 高齢者の骨代謝, 病態生理からみた骨代謝. Bone 6: 37-43, 1995

• 16) 上好昭孝: リュックサック療法-骨粗鬆症を中心に-. 治療77: 2514-2515, 1995

• 17) Chapuy MC, Arlot ME, Duboeuf F, et al: Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327: 1637-1642, 1992
  pubmed

• 18) 上好昭孝: 骨粗鬆症におけるカルシトニン有効性の評価. Clinical Calcium 6: 985-989, 1996

• 19) Watts NB, Harris ST, Gennant HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73-79, 1990

• 20) Plantalech L, Guillaumont M, Vergnaud P, et al: Impairment of gamma carboxylation of circulating osteocalcin (Bone Gla Protein) in elderly women. J Bone Miner Res 6: 1211-1216, 1991
  pubmed

• 21) Akesson K, Vergnaud P, Delmas PD, et al: : Serum osteocalcin increases during fracture healing in eldertly women with hip fracture. Bone 16: 427-430, 1995

• 22) 金木正夫, 水野有三, 細井孝之, ほか: 退行期骨粗鬆症における血清ビタミンK濃度の検討. 日本老年医学会誌 32: 195-200, 1995

• 23) Need AG, Horowitz M, Bridges A, et al: Effects of nandrolone decanoate and antiresorptivetherapy on vertebral density in osteoporotic postmenopausal women. Arch Intern Med 149: 57-60, 1989
  pubmed

• 24) Chesnut CH, Baylink DJ: The role of anabolic steroids in the treatment of osteoporosis. Geriat Med Today 2: 21-29, 1983

• 25) Lindsay R, Tohme JF: Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295, 1990
  pubmed

P.266 掲載の参考文献

• 1) 大田寛, 七川歡次, 前田晃ら: 慢性関節リウマチの死因調査 (370死亡例), 平成7年度特定疾患調査研究結果報告書 (大阪府環境保健部), 骨, pp44-65, 平成8年3月

• 2) Moritomo H, Ueda T, Komatsubara Y, et al: The risk of cancer in rheumatoid patients in Japan. Scand J Rheumatol 24: 157-159, 1995
  pubmed

• 3) 生島香, 上田孝文, 小松原良雄ら: 慢性関節リウマチ患者における悪性腫瘍発症のリスク. 臨床リウマチ (投稿中)

• 4) Matteson EL, Hickey AR, Maguire L, et al: Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 18: 809-814, 1991.

• 5) Jones M, Symmons D, Finn J, et al: Dose exposure to immunosupressive therapy increase the 10 year malignancy and mortality risk in rheumatoid arthritis?Amatched cohort study. Brit J Rheumatol 35: 738-745, 1996

• 6) Radis CD, Kahl LE, Baker GL, et al: Effects of cyclophosphamide on the developrnent of malignancy and on long-term survival of patients with rheumatoid arthritis.-A 20-year follow up study-. Arthritis Rheum 38: 1120-1127, 1995

• 7) Moder KG, Tefferi A, Menke DM, et al: Hematologic malignancises and the use of methotrexate in rheumatoid arthritis: a retrospective study. Ann J Med 99: 276-281, 1995

• 8) Bologna C, Picot M, Jorgensen C, et al: Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 56: 97-102, 1997
  pubmed

• 9) 古谷武文, 都外川新, 中島亜矢子ら: 慢性関節リウマチにおける低用量メトトレキサート療法の有害事象-自験例276例での検討-. リウマチ 36: 746-752, 1996

• 10) Georgescu L, Quinn GC, Schwartman S, et al: Lymphoma in patients with rheumatoid arthritis: association with the desease state or methotrexate treatment. Semin Arthritis Rheuma 26: 794-804, 1997

手術

P.273 掲載の参考文献

• 1) Kessler I, Vainio K: Posterior (dorsal) synovectomy for rheumatoid involvement of the hand and wrist. J Bone Joint Surg 48A: 1085-1094, 1966

• 2) Ranawat CS, Straub LR: Volar tenosynovitis of wrist in rheumatoid arthritis. Arthritis and Rhumatism 13: 112-117, 1970

• 3) Backhouse KM: Tendon involvement in the rheumatoid hand, Ann Rheurn Dis 30: 236-242, 1971
  pubmed

• 4) Gray RG, Gottlieb NL: Hand flexor tenosynovitis in rheumatoid arthritis: prevalence, distribution and associated rheumatic features. Arthritis and Rheumatism 20: 1003-1007, 1977
  pubmed

• 5) Felic DC, Clayton ML: Flexor tonosynovectomy in the rheumatoid finger. J Hand Surg 3: 364-367, 1978

• 6) Jackson IT, Paton KC: The extended approach to flexor tendon synovitis in rheumatoid arthritis. Br J PIast Surg 26: 122-131, 1988

• 7) Brown FE, Brown ML: Long term results after tenosynovectomy to treat the rheumatoid hand. J Hand Surg 13A: 704-708, 1988

• 8) Stirrat CR: Treatment of tenosynovitis in rheumatoid arthritis. Hand Clin 5: 169-175, 198

• 9) Nalebuff EA: Rheumatoid and surgery: update. J Hand Surg 8 A: 678-682, 1983
  pubmed

• 10) Stanley JK: The surgical management of the rheumatoid hand and wrist. In: Surgical Management of Rheumatoid Arthritis (Ed, Beddow FH), London, Wright, 1988

• 11) Wheen DJ, Tonkia MA, Green J, et al: Long-term results following digital flexor tenosynovectomy in rheumatoid arthritis. J Hand Surg 20A: 790-794, 1995

• 12) Tolat AR, Stanley JK, Evans RA: Flexor tenosynovectomy and tenolysis in longstanding rheumatoid arthritis: a long-term review of 49 hands. J Hand Surg 21B: 538-543, 1996

• 13) Savage R: The influence of wrist position on the minimum force required for activemovement of the interphalangeal joints. J Hand Surg 13B: 262-268, 1988

• 14) Cooney WP, Lin GT, An K-N: Improved tendon excursion following flexor tendon repair. J Hand Ther 2: 102-106, 1989

P.278 掲載の参考文献

• 1) Stone RG, Weeks LE, Hajdu M, et al: Evaluation of sciatic nerve compromise during total hip arthroplasty. Clin Orthop 201: 26-31, 1985
  pubmed

• 2) Edwards BN, Tullos HS, Noble PC: Contributory factors and etiology of sciatic nervepalsy in total hip arthroplasty. Clin Orthop 218: 136-141, 1987

• 3) Wasielewski RC, Crossett LS, Rubash HE: Neural and vascular injury in total hip arthroplasty. Orthop Clin North Am 23: 219-235, 1992
  pubmed

• 4) Nercessian OA, Piccoluga F, Eftekhar NS: Postoprative sciatic and femoral nerve palsy with reference to leg lengthening and medialization/lateralization of the hip joint following total hip arthroplasty. Clin Orthop 304: 165-171, 1994

• 5) Weber ER, Daube JR, Coventry MB: Peripheral neuropathies associated with total hip arthroplasty. J Bone Joint Surg 58-A: 66-69, 1976
  pubmed

• 6) Simmons C, Izant TH, Rothman RH, et al: Femoral neuropathy following total hip arthroplasty. J Arthroplasty 6: 559-564, 1991

• 7) Wooten SL, McLaughlin RE: Iliacus hematoma and subsequent femoral nerve palsy after penetration of the medial acetabular wall during total hip arthroplasty. Clin Orthop 191: 221-223, 1984
  pubmed

• 8) Pess GM, Lusskin R, Waugh TR, et al: Femoral neuropathy secondary to pressurized cement in total hip replacement: Treatment by decompression and neurolysis. J Bone Joint Surg 69-A: 623-625, 1987

• 9) Schwartz JT, Brumback RJ, Lakatos R, et al: Acute compartment syndrome of the thigh, J Bone Joint Surg 71-A: 392-400, 1989
  pubmed

• 10) Tani Y, Inoue K, Hukuda S: Acute compartment syndrome in the thigh after revision hip arthroplasty. Acta Orthop Scand 67: 71-72, 1996
  pubmed

• 11) Lachiewicz PF, Latimer HA: Rhabdomyolysis following total hip arthroplasty. J Bone Joint Surg 73-B: 576-579, 1991

• 12) Siliski JM, Scott RD: Obturator-nerve palsy resulting from intrapelvic extrusion of cement during total hip replacement. J Bone Joint Surg 67-B: 1225-1228, 1985

• 13) Harding K: The direct lateral approach to the hip. J Bone Joint Surg 64-B: 17-19, 1982

• 14) Ramesh M, O'Byrne JM, McCarthy N, et al: Damage to the superior gluteal nerve after the Harding approach to the hip, J Bone Joint Surg 78-B: 903-906, 1996

• 15) Weale AE, Newman P, Ferguson IT, et al: Nerve injury after posterior and direct lateral approaches for hip replacement. J Bone Joint Surg 78-B: 899-902, 1996

• 16) Black LL, Reckling FW, Porter SS: Somatosensory-evoked potential monitored during total hip arthroplasty, Clin Orthop 262: 170-174, 1991

P.285 掲載の参考文献

• 1) Nishioka J, Asahi K, Inoue K, et al: Complaint around the patella after total knee arthroplasty. Japanese J Rheum Joint Surg 6: 541-547, 1988

• 2) Campbell DG, Mintz AD, Stevenson TM: Early patellofemoral revision following total knee arthroplasty. J Arthroplasty 10: 287-291, 1995
  pubmed

• 3) Barrack RL, Wolfe MW, Waldman DA, et al: Resurfacing of the patella in total knee arthroplasty. A prospective, randomized double blind study. J Bone Joint Surg: 79-A: 1121-1131, 1997
  pubmed

• 4) Star MJ, Kaufman KR, Irby SE, et al: The effects of patellar thickness on patellofemoral forces after resurfacing. Clinical Orthopaedics 322: 279-285, 1996

• 5) Hsu H-C, Luo Z-P, Rand JA, et al: Influence of patellar thickness on patellar tracking and patellofemoral contact characteristics after total knee arthroplasty. J Arthroplasty 11: 69-80, 1996
  pubmed

• 6) Lee TQ, Gerken AP, Glaser FE, et al: Patellofemoral joint kinematics and contact pressures in total knee arthroplasty. Clinical Orthopaedics 340: 257-266, 1997

• 7) Theiss SM, Kitziger KJ, Lotke PS, et al: Component design affecting patellofemoral complications after total knee arthroplasty. Clinical Orthopaedics 326: 183-187, 1996

• 8) Andriacchi TP, Yoder D, Conley A, et al: Patellofemoral design influences function following total knee arthroplasty. J Arthroplasty 12: 243-249, 1997
  pubmed

• 9) Stiehl JB, Cherveny PM: Femoral rotational alignment using the tibial shaft axis in total knee arthroplasty, Clinical Orthopaedics 331: 47-55, 1996

• 10) Ritter MA, Herbst SA, Keating EM, et al: Patellofemoral complications following total knee arthroplasty. J Arthroplasty 11: 368-372, 1996
  pubmed

• 11) Engh GA, Parks NL, Ammeen DJ: Influence of surgical approach on lateral retinacular release in total knee arthroplasty, Clinical Orthopaedics 331: 56-63, 1996